Jing Wang, PHD
Department of Bioinformatics and Computational Biology, Division of Discovery Science
Present Title & Affiliation
Primary Appointment
Professor, Department of Bioinformatics and Computational Biology, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Professor, Department of Bioinformatics & Comp Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 1998 | University of Manitoba/National Research Council of Canada, Winnipeg, Manitoba, CA, Biophysics, Ph.D. Physics |
| 1992 | University of Manitoba, Winnipeg, Manitoba, CA, Theoretical Physics, MSc in Physics |
| 1989 | University of Winnipeg, Winnipeg, Manitoba, CA, Physics, BSc in Physics |
Postgraduate Training
| 2000-2004 | Research Associate, Bioinformatics/Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1999-2000 | Postgraduate Fellow, Biomedica Enginering in Cardiovascular Research, Texas Heart Institute/University of Texas Health Science in Houston, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Associate Professor, Department of Bioinformatics & Comp Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2011 - 2017
Assistant Professor, Department of Bioinformatics & Comp Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, 2010 - 2011
Instructor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2004 - 2010
Administrative Appointments/Responsibilities
Special Adviser for BCB Statistical Analyst, Department of Bioinformatics & Comp Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, 2009 - Present
Intramural Institutional Committee Activities
Supervisory Committee member, Benjamin Barclay Morris, Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, 2023 - Present
Supervisory Committee Member, Daniel Lin, Ph.D program, Graduate School of Biological Sciences University of Texas at Houston, 2023 - Present
Supervisory Committee Member, Yangxi Zheng, GSBS Ph.D. program, Graduate School of Biological Sciences University of Texas at Houston, 2021 - Present
Supervisory Committee member, Wei-Hsin Liu GSBS Ph.D. program, Graduate School of Biological Sciences University of Texas at Houston, 2021 - Present
Supervisory Committee Member, Jayit Biswas, GSBS Ph.D. program, Graduate School of Biological Sciences University of Texas at Houston, 2016 - 2017
Research Advisory Committee Member, Carl Michael Gay MD, Ph.D., Clinical Fellow, University of Texas MD Anderson Cancer Center, 2016 - 2019
Supervisory Committee Member, Ruchi Goonatilake, GSBS MS program, Graduate School of Biological Sciences University of Texas at Houston, 2015 - 2017
Supervisory Committee member, Shuaiping Ge , Ph.D. program, Graduate School of Biological Science University of Texas at Houston, 2014 - 2017
Supervisory, Bioinformaticain, The University of Texas MD Anderson Cancer Center, 2009 - Present
Extramural Institutional Committee Activities
member, PDXNet Data Sharing Committee, NIH, 2019 - 2022
Member, PDXNet Data Analysis Committee, NIH, 2019 - 2022
member, PDXNet Tumor volume Committee, NIH, 2018 - 2022
Editorial Activities
Editorial Board member, Cancers, 2017 - 2022
Editorial Board membe, Journal Data Mining in Genomics and Proteomics, 2011 - Present
Honors & Awards
| 2023 | Team Science Award for SCLC Research, Division of Medical Oncology, the University of Texas MD Anderson Cancer Center |
| 2001 - 2003 | Best Presentation, Duke University |
Selected Presentations & Talks
Regional Presentations
- 2000. Near-Infrared Spectroscopic Assessment of Inflammatory-Induced Atherosclerosis: A Possible Approach to Identify Unstable Plaques. Conference. 18th Houston Annual Bioengineering Conference. Houston, TX, US.
- 1995. A New Tool to Diagnose Acute Lung Injury. Invited. Annual Meeting of American College of Surgeons Manitoba Chapter. Winnipeg, Manitoba, CA.
National Presentations
- 2000. Infrared Spectroscopic Assessment of Acute Lung Injury in Critical Care Patients. Conference. Federation of Analytical Chemistry and Spectroscopy Societies (FACSS). Nashville, TN, US.
- 1999. Near-Infrared Spectroscopic Characterization of Living Human Carotid Atherosclerotic Plaques. Conference. The Eleventh Annual Symposium of Transcatheter Cardiovascular Therapeutics. Washington, DC, US.
International Presentations
- 2018. Differential Sensitivity Analysis for Resistant Malignancies: A bioinformatic approach for integrated drug screening analysis. Invited. First joined conference of France Federation of Cancer Research and MD. Anderson Cancer Center. Nice, FR.
- 2018. Cancer Informatics: Biomarker Discovery from “OMICS” Data and Application in Lung Cancer. Invited. Kunming International Cancer Research Conference. Kunming, CN.
- 2012. Clinical Assessment of Genes-Regulated-by-Methylation Developed from in Non-Small Cell Lung Cancer Cell Lines. Invited. Harbing Medical University Cancer Hospital and MD Anderson Joined Research Summit. Harbin, CN.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Dual TCR-T therapy with HPV16-targeted CD4 and CD8 TCRs to treat HPV16-positive cancers |
| Funding Source: | NIH |
| Role: | Collaborator |
| ID: | R01DE035853 |
| Date: | 2026 - 2028 |
| Title: | Exploiting Synthetic Lethality in Small Bowel Neuroendocrine Tumors with Epigenetic MTAP Loss |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | R21CA319714 |
| Date: | 2026 - 2029 |
| Title: | Novel Cholesterol-Targeting Therapies for Inflammatory Breast Cancer |
| Funding Source: | US Department of Defense |
| Role: | Collaborator |
| ID: | Grant14496205 |
| Date: | 2026 - 2031 |
| Title: | Antisense oligonucleotides to revert immune senescence, promote treatment response and prevent onset of chronic diseases |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | DP1OD042141 |
| Date: | 2026 - 2028 |
| Title: | Targeted stabilization of the tumor suppressor SMARCA4 to rewire the epigenomic state of lung cancer cells for therapeutic benefit |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | R21CA319313 |
| Date: | 2026 - 2031 |
| Title: | Distinguishing predictors of response and resistance to antibody-drug conjugates in small cell lung cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01CA315913 |
| Date: | 2026 - 2031 |
| Title: | Epithelial mechanisms of inducible antiviral resistance against AML-associated pneumonia |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01HL187192 |
| Date: | 2026 - 2031 |
| Title: | MIF pathway as a mechanism of immunotherapy resistance and therapeutical target in KEAP1-deficient non-small cell lung cancer (NSCLC) |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00026757 |
| Date: | 2026 - 2031 |
| Title: | Defining biomarkers and overcoming resistance to DLL3-targeting immune therapies in lung cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01CA302934 |
| Date: | 2026 - 2031 |
| Title: | Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01CA299092 |
| Date: | 2026 - 2031 |
| Title: | Disrupting ATF3/CGRP-IL-6 Neuroimmune Feedback to Overcome Neural Injury–Driven Immunotherapy Resistance in cSCC |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01CA311472 |
| Date: | 2025 - 2027 |
| Title: | Inducing Anti-Cancer Immunity in Pediatric High-Grade Glioma |
| Funding Source: | Hyundai Hope On Wheels |
| Role: | Collaborator |
| ID: | 1478259 |
| Date: | 2025 - 2030 |
| Title: | Targeting RNF2 to synergize with oncolytic immunovirotherapy to induce anti-cancer immunity in medulloblastoma |
| Funding Source: | NINDS |
| Role: | Co-I |
| ID: | R01NS146081 |
| Date: | 2025 - 2028 |
| Title: | The role of EphA2-YAP1 signaling in adaptive resistance to KRAS inhibition and immune suppression in NSCLC |
| Funding Source: | Cancer Prevention Research Institute of Texas |
| Role: | Co-I |
| ID: | RP260410 |
| Date: | 2025 - 2028 |
| Title: | Overcoming resistance and improving efficacy of TROP2-targeted antibody drug conjugates (ADCs) in small cell lung cancer (SCLC) |
| Funding Source: | Cancer Prevention Research Institute of Texas |
| Role: | Co-I |
| ID: | RP260254 |
| Date: | 2025 - 2030 |
| Title: | Novel patient-derived cancer models for understanding epigenetic modifications and identifying new therapeutic strategies in pancreatic neuroendocrine tumors |
| Funding Source: | NIH |
| Role: | Key |
| ID: | R01CA307063 |
| Date: | 2025 - 2028 |
| Title: | Targeting Immune-Epithelial Interaction for Lung Cancer Prevention and Therapy |
| Funding Source: | Cancer Preventention Research Institute of Texas |
| Role: | Co-I |
| ID: | RP260039 |
| Date: | 2025 - 2026 |
| Title: | Tumor expressed epigenetic regulator RNF2 as a novel immunotherapeutic target for pediatric high-grade gliomas |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Co-I |
| ID: | 00028283 |
| Date: | 2025 - 2031 |
| Title: | KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA298265 |
| Date: | 2025 - 2027 |
| Title: | Targeting RNF2 to Induce Anti-Cancer Immunity and Synergize with Oncolytic Virotherapy in Medulloblastoma and Associated Leptomeningeal Disease |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | GRANT14259024 |
| Date: | 2025 - 2030 |
| Title: | Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R01CA287279 |
| Date: | 2025 - 2027 |
| Title: | Genetically modified patient-derived organoid models and drug screening in NETs |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21CA292211 |
| Date: | 2025 - 2028 |
| Title: | Assessing migratory behaviors and metastatic ability of lung cancer cells at the single cell level |
| Funding Source: | NIH/NIBIB |
| Role: | Co-I |
| ID: | R21EB037878 |
| Date: | 2025 - 2028 |
| Title: | Developing EGFRxHER3 bispecific CAR-T cells for targeting EGFR tyrosine kinase inhibitor drug-tolerant persister cells |
| Funding Source: | Department of Defense |
| Role: | Collaborator |
| ID: | GRANT14183568 |
| Date: | 2025 - 2030 |
| Title: | Detection and elimination of drug tolerant persister cells in small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA299261 |
| Date: | 2025 - 2027 |
| Title: | Proteomics-driven precision molecular mapping of patient tumors to preclinical models in lung cancer |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | R21CA288901 |
| Date: | 2025 - 2030 |
| Title: | Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA299092 |
| Date: | 2025 - 2028 |
| Title: | KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC |
| Funding Source: | Cancer Prevention and Research Institute of Texas |
| Role: | Co-I |
| ID: | RP250222 |
| Date: | 2025 - 2028 |
| Title: | Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP250143 |
| Date: | 2025 - 2028 |
| Title: | Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETs |
| Funding Source: | Cancer Prevention & Research Institute of Texas |
| Role: | Key |
| ID: | RP250247 |
| Date: | 2025 - 2028 |
| Title: | Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC) |
| Funding Source: | Cancer Prevention Research Institute of Texas |
| Role: | collaborator |
| ID: | RP250322 |
| Date: | 2025 - 2029 |
| Title: | Targeting RNF2 to induce anti-cancer immunity and synergize with oncolytic HSV-1 in pediatric high- grade gliomas |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | FP00023172 |
| Date: | 2025 - 2028 |
| Title: | Elucidating the role of CD24 signaling in KRAS-mutant lung cancer development and response to KRAS-targeted therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP250176 |
| Date: | 2025 - 2028 |
| Title: | Investigation of ALPP/ALPG targeting as a novel strategy to overcome resistance to RET inhibitors in non-small cell lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | FP00023224 |
| Date: | 2025 - 2028 |
| Title: | Taking a BiTE out of resistance to DLL3-targeting immunotherapies in Small Cell Lung Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | FP00023062 |
| Date: | 2025 - 2028 |
| Title: | Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients with Advanced Solid Malignancies (TIGER) |
| Funding Source: | Genetech |
| Role: | Co-I |
| ID: | RCTS 64789 |
| Date: | 2025 - 2030 |
| Title: | Elucidating roles of the CD24 ligand in early lung cancer development, immune evasion and response to KRAS-targeted therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA301423 |
| Date: | 2025 - 2030 |
| Title: | Elucidating roles of the CD24 ligand in lung cancer development, immune escape and response to immune-based therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA301424 |
| Date: | 2025 - 2026 |
| Title: | Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | R21CA295906 |
| Date: | 2024 - 2029 |
| Title: | KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA298265 |
| Date: | 2024 - 2026 |
| Title: | Targeting HPK1/Axl Pathways Enhances Anti-Tumor Immunity to Overcome Adaptive Resistance to KRAS Inhibition |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA296001 |
| Date: | 2024 - 2027 |
| Title: | Developing EGFRxHER3 bispecific CAR-T cells for targeting EGFR TKI DTPCs |
| Funding Source: | Lungevity Foundation |
| Role: | Co-I |
| ID: | 2024-05 |
| Date: | 2024 - 2028 |
| Title: | BC231271: Advancing our Understanding of Metastatic Breast Cancer through Development of a Comprehensive Research Platform |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | BC231271 |
| Date: | 2024 - 2028 |
| Title: | BC231271: Advancing our Understanding of Metastatic Breast Cancer through Development of a Comprehensive Research Platform |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | BC231271 |
| Date: | 2024 - 2025 |
| Title: | Catalyzing a Cure for Oncogene Addicted Lung Cancers |
| Funding Source: | Break Through Cancer |
| Role: | Co-I |
| ID: | FP00021432 |
| Date: | 2024 - 2026 |
| Title: | Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA295906-01 |
| Date: | 2024 - 2029 |
| Title: | Optimizing Immunoradiotherapy with NBTXR3 and HCW9218: Improving Antitumor Immune Activation and Targeting TGF-β and Tumor Senescence in Breast Cancer and Melanoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA291719 |
| Date: | 2024 - 2028 |
| Title: | Novel Therapies for Osteosarcoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP240440 |
| Date: | 2024 - 2029 |
| Title: | Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA287734 |
| Date: | 2024 - 2028 |
| Title: | Biostatistics and Bioinformatics |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP240440 |
| Date: | 2024 - 2027 |
| Title: | LC230506: Mapping and Predicting Therapy Resistance in SCLC Liquid Biopsies at a Personalized Level |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | LC230506 |
| Date: | 2024 - 2029 |
| Title: | Development of immune biomarkers related to PET SUV through computational modeling for prediction of treatment response to Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA291783-01 |
| Date: | 2024 - 2029 |
| Title: | Multidimensional atlas of dynamic cellular, morphologic, and microenvironment changes driving progression of oral potentially malignant disorders |
| Funding Source: | NIH/NCI |
| Role: | MPI |
| Date: | 2024 - 2028 |
| Title: | Low-dose radiotherapy (LD-XRT) for target induction and enhancement of CAR-T cell therapy in solid tumors |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1253346 |
| Date: | 2024 - 2027 |
| Title: | LC230377 - Novel Approaches to Enhance Immune and Therapeutic Response in YAP1-Positive Recalcitrant Lung Cancers |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | GRANT13948816 |
| Date: | 2024 - 2029 |
| Title: | Novel Signaling Pathways Regulating Pancreatic Cancer Pathogenesis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2 R01 CA196941-06A1 |
| Date: | 2024 - 2029 |
| Title: | Tumor- and stromal-specific resistance mechanisms to DLL3-targeting immune therapies in lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA288618 |
| Date: | 2024 - 2028 |
| Title: | The epigenetic impact and therapeutic opportunity of AR-directed therapy for DSRCT |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP240272 |
| Date: | 2024 - 2025 |
| Title: | Evaluation of CyclinA/B RxL inhibition in pre-clinical models of SCLC |
| Funding Source: | Circle Pharma |
| Role: | Co-I |
| ID: | AWD00008239 |
| Date: | 2024 - 2027 |
| Title: | Leveraging Small-cell Lung Cancer (SCLC) liquid biopsies and single-cell proteomics for assessing therapy response and resistance at a personalized level |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP240307 |
| Date: | 2024 - 2027 |
| Title: | Development of immune biomarkers related to PET SUV through computational modeling for prediction of treatment response to Immunotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP240329 |
| Date: | 2024 - 2027 |
| Title: | Overcoming resistance mechanisms of DLL3-targeting immune therapies in lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP240113 |
| Date: | 2024 - 2027 |
| Title: | Co-targeting CDK2 and CDK4/6 can synergistically overcome resistance to CDK4/6 inhibitors in ER positive breast cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP240278 |
| Date: | 2024 - 2027 |
| Title: | Synthetic lethality of TRIP13 and Aurora kinase A in HPV-driven cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP240226 |
| Date: | 2024 - 2027 |
| Title: | Novel high-throughput approaches to identifying transcriptional and genomic mechanisms of resistance to 1st and 2nd-gen RET TKIs |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP240227 |
| Date: | 2023 - 2028 |
| Title: | Optimizing TROP2-targeted antibody-drug conjugate therapy in breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA285457-01 |
| Date: | 2023 - 2028 |
| Title: | Interrogating and targeting tumor–stroma interactions in pancreatic cancer |
| Funding Source: | NIH/NIDDK |
| Role: | Collaborator |
| ID: | 1 R01 CA279110-01A1 |
| Date: | 2023 - 2025 |
| Title: | Mapping Therapy Resistance in Patient-Derived SCLC Circulating Tumor Cells at a Personalized Level |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R21 CA286380-01 |
| Date: | 2023 - 2024 |
| Title: | Profiling the surfaceome of tumor associated myeloid derived suppressor cells (MDSCs) by phage display |
| Funding Source: | ELSA U PARDEE FOUNDATION |
| Role: | Co-PI |
| ID: | FP00018193 |
| Date: | 2023 - 2028 |
| Title: | Molecular dissection of pancreatic cancer initiation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA285648-01 |
| Date: | 2023 - 2028 |
| Title: | Dissecting Cell-Specific Immunomodulatory Functions of the IL-1B/IL-1R Pathway that Impact Lung Adenocarcinoma Development and Response to Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00019092 |
| Date: | 2023 - 2025 |
| Title: | Receptor fingerprinting of myeloid derived suppressor cells (MDSCs) by phage display |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R21 DE033224-01 |
| Date: | 2023 - 2028 |
| Title: | Lysosome-targeted therapeutic strategy for lung cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA285267-01 |
| Date: | 2023 - 2028 |
| Title: | Molecular dissection of pancreatic cancer initiation |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 R01 CA285648-01 |
| Date: | 2023 - 2028 |
| Title: | Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA276178 |
| Date: | 2023 - 2028 |
| Title: | Synthetic lethality of TRIP13 and Aurora kinase A in Rb-deficient cancer cells |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA281967-01 |
| Date: | 2023 - 2028 |
| Title: | Deciphering the mechanisms of combining MerTK antisense oligonucleotides and KRAS inhibitors on treatment efficacy and the tumor microenvironment |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| ID: | 1R01CA279446-01 |
| Date: | 2023 - 2028 |
| Title: | Targeting PPAR-d alteration and immune suppression for gastric cancer prevention and therapy |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 R01 CA282053-01 |
| Date: | 2023 - 2028 |
| Title: | Blunting senescence to enhance efficacy of the combination of checkpoint inhibitor therapy and a first-in-class nanoparticle radio-enhancer with proton or photon radiotherapy in resistant solid tumors |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| ID: | 1 R01 CA282116-01 |
| Date: | 2023 - 2028 |
| Title: | University of Texas PDX Development Center Core B: Bioinformatics Core |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | 2U54CA224065-05 |
| Date: | 2023 - 2027 |
| Title: | Nanotechnology intervention to overcome T-cell exhaustion in ovarian cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA284129-01 |
| Date: | 2023 - 2028 |
| Title: | Novel Signaling Pathways Regulating Pancreatic Cancer Pathogenesis |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 5R01CA196941-01 |
| Date: | 2023 - 2028 |
| Title: | Harnessing the Power of Artificial Intelligence to uncover new targets and potential impact of nanomedical treatments in prolonging Ovarian Cancer patient response and survival |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | 1 R01 CA283899-01 |
| Date: | 2023 - 2024 |
| Title: | Predicting SCLC Therapy Resistance from Patient Liquid Biopsies |
| Funding Source: | American Lung Association |
| Role: | Collaborator |
| ID: | FP00018131 |
| Date: | 2023 - 2028 |
| Title: | A novel therapeutic approach for Rb-deficient cancers |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | Co-I |
| ID: | FP00018295 |
| Date: | 2023 - 2024 |
| Title: | A mutation-specific tailored approach for HER2 mutant non-small cell lung cancer |
| Funding Source: | The Anne Wojcicki Foundation |
| Role: | Bioinformatician |
| ID: | FP00019029 |
| Date: | 2023 - 2026 |
| Title: | MiDAS’ touch: Dissecting the Role of Mitotic DNA Synthesis (MiDAS) in Small Cell Lung Cancer Progression |
| Funding Source: | Damon Runyon Cancer Research Foundation |
| Role: | CO-Mentor |
| ID: | FP17975 |
| Date: | 2023 - 2028 |
| Title: | Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA279194 |
| Date: | 2023 - 2028 |
| Title: | Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA272570 |
| Date: | 2023 - 2028 |
| Title: | Novel Biomimetic Tissues For Modeling the Metastatic Cascade in Aggressive Breast Cancers |
| Funding Source: | NIH/NCI |
| Role: | Bioinformatician |
| ID: | 1 U01 CA217451 - 01 |
| Date: | 2023 - 2028 |
| Title: | Dissecting Sex-Specific Immunomodulatory Mechanisms and Phenotypes that impact Lung Adenocarcinoma Development and Therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2 R01 CA225977-06 |
| Date: | 2023 - 2028 |
| Title: | Interrogating and targeting tumor–stroma interactions in pancreatic cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 R01 CA279110-01 |
| Date: | 2023 - 2028 |
| Title: | Low-dose radiotherapy (LD-XRT) in target induction and enhancement of CAR-T cell therapy in solid tumors |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| ID: | 1 R01 CA279603-01 |
| Date: | 2023 - 2026 |
| Title: | Molecular Dissection of host–environment interaction in gastric tumorigenesis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | FP00016686 |
| Date: | 2023 - 2026 |
| Title: | Low-dose radiotherapy (LD-XRT) in target induction and enhancement of CAR-T cell therapy in solid tumors |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Statistician |
| ID: | RP220261 |
| Date: | 2023 - 2027 |
| Title: | The epigenetic impact and therapeutic opportunity of AR-directed therapy for DSRCT |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP220431 |
| Date: | 2023 - 2026 |
| Title: | Novel structure-based approach to develop precision treatment strategies for primary and acquired HER2 mutations |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP230172 |
| Date: | 2023 - 2024 |
| Title: | Evaluation of AMG757 in preclinical models of SCLC |
| Funding Source: | Amgen, Inc |
| Role: | Co-I |
| ID: | AWD00007200 |
| Date: | 2023 - 2023 |
| Title: | Phenotyping Cellular Components and Assessing Potential Therapeutic Targets in SCLC Liquid Biopsies with CyTOF |
| Funding Source: | The University of Texas SPORE in Lung Cancer |
| Role: | Collaborator |
| Date: | 2023 - 2025 |
| Title: | LC220478: Application of artificial intelligence to the development of integrated radiomic and blood biomarkers to guide immunotherapy treatment in metastatic non-small cell lung cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | GRANT13686035 |
| Date: | 2023 - 2026 |
| Title: | The function of low-dose radiotherapy (LD-XRT) in target induction and enhancement of CAR-T cell therapy in solid tumors |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Collaborator |
| ID: | 979446 |
| Date: | 2023 - 2024 |
| Title: | Discovery of metastasis driver genes |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Collaborator |
| ID: | 1 R35 CA274421-01 |
| Date: | 2022 - 2027 |
| Title: | Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA 276178 -01 |
| Date: | 2022 - 2024 |
| Title: | Structure- and lineage-based classification and targeting of resistance in EGFR-mutant non-small cell lung cancer |
| Funding Source: | V Foundation |
| Role: | Collaborator |
| ID: | FP00016387 |
| Date: | 2022 - 2027 |
| Title: | Enhancing cellular and checkpoint immunotherapy for non-inflamed subgroups of SCLC |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 U01CA213273 |
| Date: | 2022 - 2027 |
| Title: | BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE U54 PROGRAM (BAATAAR-UP): Data Science Core (J. Wang's sub Project PID14443) |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| ID: | U54CA224081 |
| Date: | 2022 - 2027 |
| Title: | Molecular understanding of pancreatic cancer initiation |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 R01 CA 275960 - 01 |
| Date: | 2022 - 2027 |
| Title: | Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA272945 |
| Date: | 2022 - 2027 |
| Title: | Coordinating center for the NCI small cell lung cancer research consortium |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | U24CA213274 |
| Date: | 2022 - 2029 |
| Title: | NCI 10136-A PHASE 2 STUDY OF AZD1775, A WEE1 INHIBITOR, IN PATIENTS WITH CCNE1 AMPLIFICATION |
| Funding Source: | AstraZeneca |
| Role: | Co-I |
| ID: | AZ ESR-17-12898/D6012C00042 |
| Date: | 2022 - 2027 |
| Title: | Enhancing CAR-T activity against solid tumors by the partial inactivation of their BMP7 receptors |
| Funding Source: | NIH/NCI |
| Role: | Bioinformatician |
| ID: | 1 R01 CA 272743 - 01 |
| Date: | 2022 - 2026 |
| Title: | Vimentin phospho-malleability is critical for maintaining stemness and metastatic properties |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA262106 - 01A1 |
| Date: | 2022 - 2024 |
| Title: | LC210510: Tumor and immune cell heterogeneity pre‐ and post‐Aurora kinase inhibition and immune |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-I |
| ID: | LC210510 |
| Date: | 2022 - 2025 |
| Title: | Defining the Role of Tumor-Neutral Crosstalk in head and Neck Cancer Progression and Treatment Resistance |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R37CA242006 |
| Date: | 2022 - 2025 |
| Title: | Defining the Role of Tumor-Neutral Crosstalk in head and Neck Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 3 R37 CA242006-03S1 |
| Date: | 2022 - 2027 |
| Title: | Functional Roles of GOF TP53 Mutations in Metastasis and Immunosuppression of Head and Neck Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01DE030875 |
| Date: | 2022 - 2027 |
| Title: | DNA damaging therapy and immune response in small cell lung cancer subtypes |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA207295 |
| Date: | 2022 - 2024 |
| Title: | Tumor cell-intrinsic factors that underlie immunosuppression mechanism in head and neck squamous cell carcinoma |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | 1 R03 DE 031844 - 01 |
| Date: | 2022 - 2024 |
| Title: | Novel structure-based and combinational approaches for RET-fusion NSCLC |
| Funding Source: | Lungevity Foundation |
| Role: | Co-I |
| ID: | AWD00006627 |
| Date: | 2022 - 2025 |
| Title: | Studying the function of low-dose radiotherapy (LD-XRT) in enhancing the efficacy of CAR T cell therapy for solid tumors |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Date: | 2021 - 2024 |
| Title: | Multiparametric Immunoprofiling to Characterize Low vs. High Tumor Mutational Burden Driven Immune Microenvironment in Esophagogastric Adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 K22 CA266741-01 |
| Date: | 2021 - 2024 |
| Title: | Pending |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | FP00012870 |
| Date: | 2021 - 2026 |
| Title: | Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA262425 |
| Date: | 2021 - 2023 |
| Title: | Understanding the role of oral trauma and pathogenic bacteria in oral cancer development |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | Pending |
| Date: | 2021 - 2026 |
| Title: | Novel and highly specific therapeutic strategy for targeting the lysosomal pathway in cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA265747-01 |
| Date: | 2021 - 2023 |
| Title: | A novel epigenetic mechanism to define chemotherapy-induced autophagy outcome in Osteosarcoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R21 CA273982-01 |
| Date: | 2021 - 2026 |
| Title: | Molecular understanding of pancreatic cancer initiation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA248102 - 01A1 |
| Date: | 2021 - 2026 |
| Title: | Targeting the tumor stroma with low-dose radiation in order to overcome immunotherapy resistance |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R01 CA266368 |
| Date: | 2021 - 2024 |
| Title: | Impact of tumor mutation burden on immune microenvironment of esophagogastric adenocarcinomas |
| Funding Source: | Department of Defense (DOD) |
| Role: | Collaborator |
| ID: | W81XWH-20-PRCRP-CDA |
| Date: | 2021 - 2026 |
| Title: | Molecular subtypes as predictors for precision small cell lung cancer therapeutic response |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP210159 |
| Date: | 2021 - 2026 |
| Title: | Targeting replication stress and homologous recombination repair mechanisms in HPV-positive and negative head and neck cancer |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | R01DE030104 |
| Date: | 2021 - 2023 |
| Title: | Discovery of novel molecular targets in head and neck squamous cell carcinoma by phage display |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R03DE030514-01A1 |
| Date: | 2021 - 2026 |
| Title: | Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U01CA256780 |
| Date: | 2021 - 2026 |
| Title: | Molecular Understanding and Targeting of Determinant Factors in Gastric Tumorigenesis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA236905 |
| Date: | 2021 - 2026 |
| Title: | Understanding Neuro-Immune Crosstalk to Achieve Tissue Robustness in Oral Cavity Squamous Cell Carcinoma |
| Funding Source: | NIH/NIDCR |
| Role: | OSC |
| ID: | 1R01DE030482-01 |
| Date: | 2021 - 2026 |
| Title: | Immunomodulation of the tumor stroma with low-dose radiation to improve the efficacy of NK cell therapy for solid tumors |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA258422 |
| Date: | 2021 - 2026 |
| Title: | Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA248731 |
| Date: | 2020 - 2025 |
| Title: | The role of epithelial-mesenchymal transition in modulating responses to lung cancer immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA254983 |
| Date: | 2020 - 2025 |
| Title: | Mutant p53 gains oncogenic functions through a cytosolic DNA response |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 DE029449 |
| Date: | 2020 - 2020 |
| Title: | The interplay of inflammation, genomic instability, and immune microenvironment in oral cancer development |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | R03 DE029521-01A1 |
| Date: | 2020 - 2022 |
| Title: | Viral Replication Pathways During Oral Tumorigenesis and Response to Therapy |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | 5 R01 DE027445-03 |
| Date: | 2020 - 2025 |
| Title: | Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA247975 |
| Date: | 2020 - 2023 |
| Title: | Investigating the role of CD38 as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP200235 |
| Date: | 2020 - 2024 |
| Title: | Harnessing immune pathways in RBM10-deficient KRAS-mutant NSCLC |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-I |
| Date: | 2019 - 2024 |
| Title: | Therapeutic strategies against EGFR exon 20 mutant lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 R01 CA234183-05 |
| Date: | 2019 - 2023 |
| Title: | University of Texas PDX Development and Trial Center |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| ID: | 5 U54 CA224065-04 |
| Date: | 2019 - 2024 |
| Title: | Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 R01 CA235620-05 |
| Date: | 2019 - 2020 |
| Title: | University of Texas PDX Development and Trial Center |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U54 CA224065-02S1 |
| Date: | 2019 - 2022 |
| Title: | CPRIT-MIRA: Rational Combination Treatment Options to Reverse Resistance in Hormone Receptor Positive Breast Cancer Refractory to Standard Therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Core Leader |
| ID: | RP180712 |
| Date: | 2019 - 2021 |
| Title: | SPORE Core C: Developing New Rationale, Personalized Medicine for Lung Cancer |
| Funding Source: | NIH/NCI via subaward UT Southwestern Medical Center |
| Role: | Co-Program Leader |
| ID: | 2 P50 CA070907-21A1 |
| Date: | 2019 - 2022 |
| Title: | Molecular dissection of pancreatic cancer initiation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA222394 |
| Date: | 2019 - 2024 |
| Title: | Investigating the role of CD38 as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2019 - 2024 |
| Title: | The interdependency of CD38 and EMT determines the outcome of anti-PD-1/CTLA-4 immunotherapy in lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA244264 |
| Date: | 2019 - 2021 |
| Title: | Impact of tumor and immune cell heterogeneity on CAR T-cell therapy response in small cell lung cancer (SCLC) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP190508 |
| Date: | 2019 - 2026 |
| Title: | Cancer Center Support (CORE) Grant |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P30CA016672 |
| Date: | 2019 - 2024 |
| Title: | Genetic and Epigenetic Biomarkers for B-cell Lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA233490 |
| Date: | 2019 - 2024 |
| Title: | Cell-free DNA (cfDNA) to detect minimal residual disease, predict therapeutic response, and characterize immunogenomic evolution in early-stage NSCLC treated with neoadjuvant immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Date: | 2019 - 2024 |
| Title: | Harnessing polo-like kinase 1 inhibitor-induced apoptosis in lung cancer treatment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2019 - 2022 |
| Title: | Role of intra-tumoral heterogeneity in CAR-T cell response in lung cancer |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Collaborator |
| Date: | 2019 - 2024 |
| Title: | Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell Carcinoma |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | 5 R01 DE028061 - 04 |
| Date: | 2019 - 2023 |
| Title: | Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2018 - 2021 |
| Title: | Tumor and immune cell heterogeneity during CAR T-cell therapy in small cell lung cancer (SCLC) |
| Funding Source: | The Mark Foundation for Cancer Research |
| Role: | Co-I |
| ID: | Emerging Leader Award - 20784 |
| Date: | 2018 - 2021 |
| Title: | Combined Effects of Simulated Microgravity and Space Radiation on Human Cells |
| Funding Source: | Prairie View A&M |
| Role: | Co-I |
| ID: | 80NSSC19K0133 |
| Date: | 2018 - 2019 |
| Title: | University of Texas PDX Development and Trial Center |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| ID: | U54 CA224065 |
| Date: | 2018 - 2022 |
| Title: | Comparative study on the effects of e-cigarette vapor versus cigarette smoke on COPD development and lung cancer promotion |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2018 - 2023 |
| Title: | Improving Immunotherapy in Head and Neck Squamous Cell Carcinoma Through Modulation of Caspase-8 |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA233506 |
| Date: | 2018 - 2023 |
| Title: | Therapeutic strategies against EGFR exon 20 mutant lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2018 - 2025 |
| Title: | Targeting Lung Cancer Vulnerabilities_Lung SPORE BCB Core C |
| Funding Source: | NIH/NCI |
| Role: | Program Leader |
| ID: | P50CA070907 |
| Date: | 2018 - 2024 |
| Title: | Pediatric Solid Tumors Comprehensive Data Resource Core |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP180819 |
| Date: | 2018 - 2024 |
| Title: | Core 3: Rational Combination Treatment Options to Reverse Resistance in Hormone Receptor Positive Breast Cancer Refractory to Standard Therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Core Leader |
| ID: | RP180712 |
| Date: | 2018 - 2022 |
| Title: | Targeting the interplay between EMT and the immune system for effective immunotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Date: | 2018 - 2023 |
| Title: | Defining Protective Responses in Hematopoietic Cells Mediated by STAT3 Anti-Inflammatory Activity |
| Funding Source: | NIH/NIAID |
| Role: | Co-I |
| ID: | 1R01AI133822-01 |
| Date: | 2018 - 2020 |
| Title: | Pro-Inflammatory Conversion of the PDAC Microenvironment |
| Funding Source: | Pancreatic Cancer Action Network (PanCAN) |
| Role: | Collaborator |
| Date: | 2018 - 2023 |
| Title: | Novel Therapeutic Strategies to Target Replication Stress for the Treatment of High risk HPV-driven HNSCC |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | 1R01DE026470-01A1 |
| Date: | 2018 - 2023 |
| Title: | Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2018 - 2023 |
| Title: | The impact of tumor molecular features and host immune reactions on clinical outcome in melanoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2018 - 2023 |
| Title: | PPAR-d regulation of gastric progenitor cell stemness and tumorigenesis |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Date: | 2018 - 2019 |
| Title: | Evaluation of AXL targeting and combination strategies in NSCLC and other tumor types |
| Funding Source: | Genmab |
| Role: | Co-I |
| ID: | PA16-0061 |
| Date: | 2018 - 2021 |
| Title: | LC170171 Tumor heterogeneity and therapeutic resistance in small cell lung cancer (SCLC) |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | W81XWH-18-1-0091 |
| Date: | 2018 - 2023 |
| Title: | Defining Protective Responses in Hematopoietic Cells Mediated by STAT3 Anti-Inflammatory Activity |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 R01 CA133822-05 |
| Date: | 2018 - 2023 |
| Title: | Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 R01 CA 225977-03 |
| Date: | 2018 - 2021 |
| Title: | DISARM (Differential Sensitivity Analysis of Resistant Malignancies): A computational approach to identify candidate drugs and biomarkers in resistant cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP180254 |
| Date: | 2018 - 2022 |
| Title: | A somatic mutant p53 mouse model of metastatic triple negative breast cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP180313 |
| Date: | 2018 - 2021 |
| Title: | Preventing therapy-related leukemia and myelodysplastic syndromes in Texas |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP180583 |
| Date: | 2018 - 2021 |
| Title: | The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer and the Tumor Microenvironment |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP180035 |
| Date: | 2018 - 2022 |
| Title: | Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP180218 |
| Date: | 2018 - 2021 |
| Title: | Molecular Drivers of Adenoid Cystic Carcinoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP180354 |
| Date: | 2018 - 2020 |
| Title: | Evaluation of the CHK1 inhibitor, SRA737, in preclinical models of small cell lung cancer |
| Funding Source: | Sierra Oncology, Inc |
| Role: | Co-I |
| ID: | 100950 |
| Date: | 2018 - 2022 |
| Title: | Validation of Critical 1q21 Vulnerabilities in Multiple Myeloma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 R01 CA222253-05 |
| Date: | 2018 - 2022 |
| Title: | Restoration of TGF-BETA Tumor Suppressor Functions as a Novel Therapeutic Strategy for Advanced Stage Liver Cancer |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-I |
| Date: | 2018 - 2021 |
| Title: | Restoration of TGF-β Tumor Suppressor Function as a Novel Therapeutic Strategy for Advanced Stage Liver Cancer |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-I |
| ID: | FP00000206_Res1 |
| Date: | 2018 - 2024 |
| Title: | The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 4 R37 CA214609-05 |
| Date: | 2017 - 2021 |
| Title: | Detection, Characterization & Immunoprevention of Pre & Early Lung cancers |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Co-I |
| Date: | 2017 - 2020 |
| Title: | CD37 B-cell antigen as an important biomarker for immunotherapy in aggressive lymphoma |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Co-I |
| ID: | TRP-12483-17 |
| Date: | 2017 - 2020 |
| Title: | University of Texas PDX Development and Trial Center Bioinformatics Core |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U54 CA224065 |
| Date: | 2017 - 2022 |
| Title: | FOXK2 aberration in breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA205081-01A1 |
| Date: | 2017 - 2022 |
| Title: | Mechanisms of Adenoid Cystic Carcinoma Development and Tumor Maintenance |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01DE026735-01A1 |
| Date: | 2017 - 2022 |
| Title: | Exploiting molecular characteristics with protons to improve treatment benefits |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2017 - 2022 |
| Title: | PPAR-d regulation of gastric progenitor cell stemness and tumorigenesis |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Date: | 2017 - 2022 |
| Title: | Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 U01 CA213273-05 |
| Date: | 2017 - 2019 |
| Title: | Gender-specific function of epithelial STAT3 in K-ras mutant lung cancer |
| Funding Source: | American Lung Association |
| Role: | Co-I |
| Date: | 2017 - 2022 |
| Title: | The impact of tumor molecular features and host immune reactions on clinical outcome in melanoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2017 - 2022 |
| Title: | Autocrine and paracrine mechanisms for gender and cell type specific function of IL-6/STAT3 signaling in K-ras mutant lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA211189 |
| Date: | 2017 - 2022 |
| Title: | SPORE for Immunologic Approaches to HPV-Related Cancers – Biostatistics and Bioinformatics Core (Core 2) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1P50CA214676-01 |
| Date: | 2017 - 2022 |
| Title: | MD Anderson Cancer Center Head & Neck SPORE - Biostatistics and Bioinformatics Core (Core B) |
| Funding Source: | NIH/NCI |
| Role: | Core Director |
| ID: | 1P50CA217669-01 |
| Date: | 2017 - 2019 |
| Title: | (PQ1) The Role of p53 Mutations in Immunoprevention of Progression of Oral Premalignant Lesions |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA219466-01 |
| Date: | 2017 - 2021 |
| Title: | Exploiting molecular characteristics of protons to improve treatment benefits |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2017 - 2022 |
| Title: | Targeting polo-like kinase 1 in mesenchymal non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2017 - 2020 |
| Title: | Gender and cell type specific function of STAT3 in K-ras mutant lung cancer |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Co-I |
| Date: | 2017 - 2020 |
| Title: | Evaluation of the Axl inhibitor TP0903 in preclinical models of lung, breast and head and neck cancer |
| Funding Source: | Tolero Pharmaceuticals |
| Role: | Co-I |
| ID: | C407B4A1-A9A1-416EE7—BCC099B714F0 |
| Date: | 2017 - 2020 |
| Title: | Evaluation of DDR inhibitors and immunotherapy in preclinical models of NSCLC |
| Funding Source: | AstraZeneca |
| Role: | Co-I |
| Date: | 2017 - 2020 |
| Title: | Evaluation of DDR inhibitors and immunotherapy in preclinical models of NSCLC |
| Funding Source: | AstraZeneca |
| Role: | Co-I |
| Date: | 2017 - 2022 |
| Title: | Enhancing Chemoradiation Efficacy Through Unbiased Drug Discovery Approaches |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 U01 CA 216468 - 05 |
| Date: | 2017 - 2019 |
| Title: | Targeting DNA damage to improve treatment gain from protons/photons radiotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2017 - 2022 |
| Title: | The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2017 - 2019 |
| Title: | Mechanisms and Consequences of NOTCH Dysfunction in Head and Neck Cancer |
| Funding Source: | NIH via subaward Baylor College of Medicine |
| Role: | Co-I |
| ID: | R01 DE024179 |
| Date: | 2016 - 2018 |
| Title: | Aurora Kinase Pathway Targeted Therapeutics for Small Cell Lung Cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-I |
| Date: | 2016 - 2021 |
| Title: | 15-LOX-1 Regulation of Resolving Generation to Modulate Colon Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 R01 CA195686 |
| Date: | 2016 - 2017 |
| Title: | Overcoming Platinum Resistance via Targeting the Proteasome in Cancer Cells |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2016 - 2021 |
| Title: | Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing |
| Funding Source: | NIH/NCI |
| Role: | Significant Contributor |
| ID: | 5R01CA190628 |
| Date: | 2016 - 2021 |
| Title: | Therapeutic strategies for targeting PARP1 in small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 R01 CA 207295 |
| Date: | 2016 - 2021 |
| Title: | Mechanisms of sensitivity and resistance to polo-like kinase inhibitors in non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA207380-01 |
| Date: | 2016 - 2022 |
| Title: | Defining and Defeating Mechanistic Subtypes of KRAS-mutant Lung Cancers; Core 2: Bioinformatics – Clinical Investigational Data Analytics |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Core Leader |
| ID: | RP160652 |
| Date: | 2016 - 2019 |
| Title: | Mechanisms of carcinogenesis and therapeutic vulnerabilities associated with RBM10 loss in KRAS mutant NSCLC |
| Funding Source: | Department of Defense Lung Cancer Development Award |
| Role: | Co-I |
| ID: | W81XWH-15-LCRP-CDA |
| Date: | 2016 - 2018 |
| Title: | Modeling the biological and therapeutic implications of APOBEC mutagenesis in NSCLC |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP160741 |
| Date: | 2015 - 2017 |
| Title: | Defining and Treating Targetable Lesions in AYA Acute Lymphoblastic |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP150006 |
| Date: | 2015 - 2016 |
| Title: | Spore in Head and Neck Cancer - Comprehensive Genomic Characterization of HNSCC Arising in HIV-Infected Individuals |
| Funding Source: | NIH/NIDCR Subaward with Johns Hopkins University |
| Role: | Co-I |
| ID: | P50 DE019032 |
| Date: | 2015 - 2017 |
| Title: | Chk1 as a Novel Target in Small Cell Lung Cancer (SCLC) |
| Funding Source: | American Lung Association |
| Role: | Co-I |
| Date: | 2015 - 2020 |
| Title: | Epithelial-mescenchymal Transition and Immunosuppression in Lung Adenocarcinoma Invasion and Metastasis |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | PA 13-301 |
| Date: | 2015 - 2020 |
| Title: | Defining and Defeating Mechanistic Subtypes of KRAS-Mutant Lung Cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP150519 |
| Date: | 2015 - 2019 |
| Title: | (PQD4) Molecular Profiles of Airway Field Cancerization in Lung Tumorigenesis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA184742 |
| Date: | 2015 - 2018 |
| Title: | Identification of Clinically Relevant Targets for Radiosensitization |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP150293 |
| Date: | 2015 - 2016 |
| Title: | Biological and Clinical Significance of the NOTCH Pathway in Head and Neck Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP150190 |
| Date: | 2015 - 2018 |
| Title: | Tumor Cell Epithelial-Mesenchymal Transition in Regulating Immunosuppression and Metastis in Lung Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP150405 |
| Date: | 2015 - 2018 |
| Title: | Progression of Metastasis of Oral Tongue Cancer |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | R01 DE014613 |
| Date: | 2014 - 2017 |
| Title: | Inhibiting Oxidative Phosphorylation: A Novel Strategy in Leukemia |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Co-I |
| Date: | 2014 - 2019 |
| Title: | 3D Model of Human Ewing Sarcoma |
| Funding Source: | NIH via subaward Rice University |
| Role: | Co-I |
| ID: | R01 CA180279 |
| Date: | 2014 - 2019 |
| Title: | SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer - Core C |
| Funding Source: | University of Texas Southwestern Medical Center-Dallas (Subcontract with NIH) |
| Role: | Co-I |
| ID: | 5P50CA70907 |
| Date: | 2014 - 2019 |
| Title: | MD Anderson Oropharynx Program Bioinformatics |
| Funding Source: | Stiefel Oropharyngeal Research Fund |
| Role: | Core Director |
| ID: | 600815-80-114516-21 |
| Date: | 2014 - 2017 |
| Title: | Next Generation Sequencing and Transcriptome Profiling of Oral Potentially Malignant Lesions to Identify Markers of Cancer Risk and Targets for Chemoprevention |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP140464 |
| Date: | 2014 - 2019 |
| Title: | Developing New Rational, Personalized Medicine for Lung Cancer Based on Understanding of Lung Cancer Molecular and Cellular Biology |
| Funding Source: | UT Southwestern Medical Center |
| Role: | Co-I |
| ID: | P50 CA070907 |
| Date: | 2014 - 2019 |
| Title: | "BRAF Dimerization as a Therapeutic Target in NSCLC" |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA184873-01 |
| Date: | 2014 - 2016 |
| Title: | Impact of NF1 inactivation on the pathogenesis, signaling circuitry and therapeutic responsiveness of NSCLC in a novel co-clinical trial of targeted therapy |
| Funding Source: | Uniting Against Lung Cancer |
| Role: | Co-I |
| ID: | 13127251 |
| Date: | 2014 - 2016 |
| Title: | Identifying biomarkers of sensitivity to polo-like kinase (Plk) inhibitors in Non-Small-Cell Lung Cancer (NSCLC) |
| Funding Source: | Uniting Against Lung Cancer |
| Role: | Co-I |
| Date: | 2014 - 2016 |
| Title: | Integrative, cross-species interrogation of the impact of NF1 inactivation on the pathogenesis, signaling circuitry and treatment responsiveness of non-small cell lung cancer |
| Funding Source: | Uniting Against Lung Cancer |
| Role: | Co-I |
| Date: | 2014 - 2016 |
| Title: | Stress Hormones as Mediators of Drug Resistance in NSCLC |
| Funding Source: | Uniting Against Lung Cancer |
| Role: | Co-I |
| Date: | 2013 - 2014 |
| Title: | A Therapeutic Approach for Lung Cancer Chemoprevention |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP110107 |
| Date: | 2013 - 2014 |
| Title: | Integrating The Power of Clonogenic Survival Assay To Discover New Radiation Sensitizers From Established Drugs or To Identify New Protein Targets |
| Funding Source: | StCube, Inc |
| Role: | Co-I |
| Date: | 2013 - 2018 |
| Title: | Stromal Contributions in the Tumor Microenvironment of Oral Cancer |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | 1 R01 DE022845-01 |
| Date: | 2013 - 2014 |
| Title: | Investigation of predictive biomarkers for amuvatinib in patients with refractory small cell lung cancer (SCLC) |
| Funding Source: | Astex Therapeutics |
| Role: | Co-I |
| ID: | LAB10-0849 |
| Date: | 2013 - 2018 |
| Title: | Alternate Antiangiogenic Therapy Dosing: A Novel Approach to Overcoming Resistance |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Date: | 2013 - 2015 |
| Title: | Investigation of Moleular Drivers in Young Adults with Non-small Cell Lung Cancer |
| Funding Source: | Uniting Against Lung Cancer |
| Role: | Co-I |
| Date: | 2013 - 2014 |
| Title: | Mutational Profiling to Identify Driver Genes in Young Lung Cancer Patients |
| Funding Source: | The Bonnie J. Addario Lung Cancer Foundation |
| Role: | Co-I |
| Date: | 2013 - 2013 |
| Title: | Investigation of Moleular Drivers in Young Adults with Non-small Cell Lung Cancer |
| Funding Source: | Phi Beta Psi Sorority |
| Role: | Co-I |
| Date: | 2012 - 2015 |
| Title: | Novel Molecular Mechanisms of Dietary DIM in Pancreatic Cancer Prevention and Therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP130030 |
| Date: | 2012 - 2014 |
| Title: | Identification of molecular targets and pathways that contribute to drug sensitivity or resistance to the MEK inhibitor AZD6244 alone or in combination with PI3k/AKT inhibitors in NSCLC |
| Funding Source: | AstraZeneca |
| Role: | Co-I |
| ID: | AstrZeneca-01 |
| Date: | 2012 - 2017 |
| Title: | Activation of Spermatogenic Recovery After Toxic Insult |
| Funding Source: | NIH/NIEHS |
| Role: | Co-I |
| ID: | 2 R01 ES008075 16A1 |
| Date: | 2012 - 2015 |
| Title: | PARP1 as a Novel Therapeutic Target in SCLC |
| Funding Source: | LUNGevity Foundation |
| Role: | Co-I |
| ID: | LUNG-01 |
| Date: | 2012 - 2016 |
| Title: | Stromal Determinants of Lymphatic Metastasis in Head and Neck Cancer |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-I |
| Date: | 2011 - 2016 |
| Title: | Markers and Therapeutic Strategies for Overcoming Chemoradiotherapy Resistance |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA168484 |
| Date: | 2011 - 2012 |
| Title: | Development of a 4-gene signature to predict disease control in patients with EGFR and KRAS wild-type non-small cell lung cancer treated with erlotinib |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Investigator |
| Date: | 2011 - 2016 |
| Title: | Extension of Radio Therapy Research (PC-B) |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 2 P01 CA006294 45A2 |
| Date: | 2011 - 2016 |
| Title: | FGF Signaling in Prostate Cancer Stem Cells and Prostate Cancer Bone Progression |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA160319 01 |
| Date: | 2010 - 2015 |
| Title: | Epigenetic Regulation of Tumor Growth by Anti-HER2 Antibody Trastuzumab |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 R01 CA155122 01 |
| Date: | 2010 - 2011 |
| Title: | University of Texas SPORE in Lung Cancer - "PARP Inhibition to Overcome Radiation Resistance in Small Cell Lung Cancer - (CL 30696)" PP-CDP 17 |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| ID: | P50 CA070907 |
| Date: | 2010 - 2013 |
| Title: | Comprehensive Analysis of Genetic and Epigenetic Changes in Oral Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP100233-02 |
| Date: | 2010 - 2015 |
| Title: | Validation and Expansion of Radioresponse-Driven Individualized Cancer Therapy (VERDICT) (PC-B) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Investigator |
| ID: | RP101242 |
| Date: | 2010 - 2013 |
| Title: | Comprehensive Analysis of Genetic Alterations in Oral Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP100233 |
| Date: | 2010 - 2015 |
| Title: | Effect of Hypoxia on Tumor Biomarker Identification |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA148873 01 |
| Date: | 2010 - 2015 |
| Title: | Molecular Analysis of Human Breast Cancer to Facilitate Patient Selection for Novel Therapy (PC-B) |
| Funding Source: | NIH/NCI |
| Role: | Lead Statistician |
| ID: | 1 P01 CA148097 01 |
| Date: | 2009 - 2014 |
| Title: | Beta-Catenin and Prostate Cancer Bone Metastases |
| Funding Source: | NIH/NCI |
| Role: | Instructor |
| ID: | 1 R01 CA134769 01A1 |
| Date: | 2009 - 2012 |
| Title: | Comprehensive Analysis of Genetic Alterations in Oral Cancer |
| Funding Source: | NIH/NIDCR |
| Role: | Collaborator |
| ID: | RC2 DE020958 |
| Date: | 2009 - 2011 |
| Title: | Novel IGF-iR-based Therapy of Patients with Untreated Sarcomas |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 RC1 CA145946 01 |
| Date: | 2009 - 2011 |
| Title: | Targeted Delivery miR-200-bound Gold Nanorods in Urothelial Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 RC1 CA148792 01 |
| Date: | 2009 - 2011 |
| Title: | Nuclear Export of mRNA Under Hypoxioa: Profiling and Mechanistic Studies |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 RC1 CA146355 01 |
| Date: | 2009 - 2011 |
| Title: | Enhancing the Efficacy of Androgen Ablation in Advanced Prostate Cancer by Hedgeh |
| Funding Source: | NIH/NCI |
| Role: | Statisician |
| ID: | 1 RC1 CA146956 01 |
| Date: | 2009 - 2011 |
| Title: | Protein Fingerprints of Fresh Lung Cancer Samples |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 RC1 CA144406 01 |
| Date: | 2009 - 2010 |
| Title: | Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination AKA Battle II (PC-J) |
| Funding Source: | Cohen-Reinach Family Charitable Foundation |
| Role: | Investigator |
| ID: | BATTLE 02 |
| Date: | 2009 - 2009 |
| Title: | Validation of Proteomic Signature of Penetrexed Resistance in NSCLC and Investigation of New Therapeutic Targets Identified by the Signature |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Collaborator |
| Date: | 2008 - 2013 |
| Title: | Plasma cytokine/angiogenic factor profiling to predict NSCLC therapeutic response |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 R01 CA137118 01 |
| Date: | 2008 - 2009 |
| Title: | MD Andersonc Cancer Center Head and Neck SPORE (PP-CDP1) |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 2 P50 CA097007 06A1 |
| Date: | 2007 - 2012 |
| Title: | PROSPECT (Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evalutation of Cancers of the Thorax and Therapeutic Target identification) PC-B |
| Funding Source: | Department of Defense (DOD) |
| Role: | Bioinformatician |
| ID: | W81XWH 07 1 0306 04 |
| Date: | 2006 |
| Title: | Synthetic lethality screening for the identification of targets synergistic with P13 kinase inibition |
| Funding Source: | Sontag Foundation Distinguished Scientist Award |
| Role: | Collaborator |
| Date: | 2006 - 2011 |
| Title: | Deciphering synergistic combinatorial targets in glioma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R01 CA123304 |
| Date: | 2006 |
| Title: | c-Jun in chemoresistance of cancer cells to platinum compounds |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Collaborator |
| Date: | 2005 - 2006 |
| Title: | Evaluation of TAU Protein Expression as a Marker of Benefit from Paclitaxel Containing Adjuvant Chemotherapy for Breast Cancer. Analysis of the NSABSP-B-28 Study |
| Funding Source: | The Breast Cancer Research Foundation Grant |
| Role: | Collaborator |
| ID: | 01 |
| Date: | 2004 |
| Title: | Development of methods for meta-analysis of microarray gene expression data to identify biomarkers for prognosis and tumor sub-classification |
| Funding Source: | UT M.D. Anderson Cancer Center Institutional Research Grant |
| Role: | PI |
| Date: | 2003 - 2009 |
| Title: | VITAL (Vanguard Investigations of therapeutic approaches to lung cancer) PC-B |
| Funding Source: | Department of Defense (DOD) |
| Role: | Collaborator |
| ID: | W81XWH-04-1-0142 05 |
| Date: | 2003 - 2004 |
| Title: | Calibrating oligo-based cDNA microarray data through modeling nucleotide interactions on microarray surface |
| Funding Source: | UT M.D. Anderson Cancer Center Institutional Research Grant |
| Role: | Collaborator |
| Date: | 2002 - 2015 |
| Title: | MD Anderson Cancer Center Head & Neck SPORE (PP-DRP4) |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 5P50CA097007-10 |
| Date: | 2002 - 2014 |
| Title: | MD Anderson Cancer Center Head & Neck SPORE (PP-DRP4) |
| Funding Source: | NIH/NCI |
| Role: | Biostatistican |
| ID: | 5P50CA097007-10 |
| Title: | Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients with Advanced Solid Malignancies (TIGER) |
| Funding Source: | Genetech |
| Role: | Co-I |
| ID: | RCTS 64789 |
| Title: | Comprehensive Analysis of Genetic Alterations in Oral Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | 35612 |
| Title: | Defining the Mutator Phenotype in Renal Cell Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 00014594 |
Selected Publications
Peer-Reviewed Articles
- Wang J. Fgl2-knockout tumor cells serve as a vaccine inducing long-duration brain-resident memory T cells that reject subsequent intracranial tumor cell challenges. Cancer Lett, 2026. e-Pub 2026. PMID: 41380903.
- Wang J. STAT3 mediates an inflammation-induced microbial defense response and regulates pathogen control and clearance by macrophages. J Immunol , 2026. e-Pub 2026. PMID: 41216965.
- Wang J. Antigen presentation requirements for effective cDC1-based cancer immunotherapy, 2026. e-Pub 2026. PMID: 41659662.
- Wang J. CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. Nat Communication, 2026. e-Pub 2026. PMID: 41571637.
- Wang J. The impact of targeting TRAF2 and NCK-interacting protein kinase (TNIK) on anti-tumor effect and tumor immune environment in c-MYC-high small cell lung cancer. J Thorac Oncol , 2025. e-Pub 2025. PMID: 41456708.
- Wang J. Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts, 2025. e-Pub 2025. PMID: 41442499.
- Wang J. CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized level, 2025. e-Pub 2025. PMID: 41446220.
- Wang J. Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples. Eur Urol Oncol , 2025. e-Pub 2025. PMID: 41193273.
- Wang J. Combined inhibition of lysine-specific demethylase 1 and kinase signaling as a preclinical treatment strategy in glioblastoma. Neurooncol Adv , 2025. e-Pub 2025. PMID: 41497449.
- Freitas-Cortez, MA, Masrorpour, F, Jiang, H, Mahmud, I, Lu, Y, Huang, A, Duong, LK, Wang, Q, Voss, TA, Kettlun Leyton, C, Wei, B, Chan, W, Lin, H, Zhang, J, Tsouko, E, Ganjoo, S, Barsoumian, H, Riad, TS, Hu, Y, Leuschner, C, Puebla-Osorio, N, Wang, J, Hu, J, Davies, MA, Puduvalli, VK, Billon, C, Burris, TP, Lorenzi, PL, Gan, B, Welsh, J. Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins. Molecular cancer 24(1), 2025. e-Pub 2025. PMID: 39901247.
- Korde, A, Ramaswamy, A, Anderson, S, Jin, L, Zhang, JG, Hu, B, Velasco, WV, Diao, L, Wang, J, Pisani, MA, Sauler, M, Boffa, DJ, Puchalski, J, Yan, X, Moghaddam, SM, Takyar, SS. Cigarette smoke induces angiogenic activation in the cancer field through dysregulation of an endothelial microRNA. Communications Biology 8(1), 2025. e-Pub 2025. PMID: 40155749.
- Luo, L, Yang, P, Mastoraki, S, Rao, X, Wang, Y, Kettner, NM, Singareeka Raghavendra, A, Tripathy, D, Damodaran, S, Hunt, KK, Wang, J, Li, Z, Keyomarsi, K. Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer. Molecular cancer 24(1), 2025. e-Pub 2025. PMID: 39955556.
- Morris, BB, Heeke, S, Xi, Y, Diao, L, Wang, Q, Rocha, P, Arriola, E, Lee, MC, Tyson, DR, Concannon, KF, Ramkumar, K, Stewart, CA, Cardnell, R, Wang, R, Quaranta, V, Wang, J, Heymach, JV, Nabet, BY, Shames, DS, Gay, CM, Byers, LA. DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer. Molecular cancer 24(1), 2025. e-Pub 2025. PMID: 40114214.
- Wang J. Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers. Cancer Discovery, 2025. e-Pub 2025. PMID: 40358390.
- Wang J. Lung cell transplantation for pulmonary fibrosis. Sci Adv, 2025. e-Pub 2025. PMID: 39178253.
- Wang J. Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF(V600E) metastatic colorectal cancer. Cancer Cell, 2025. e-Pub 2025. PMID: 40882637.
- Wang J. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature, 2025. e-Pub 2025. PMID: 40836096.
- Shah, P, Mazumdar, T, Ghosh, S, Yapindi, L, Powell, RT, Park, YS, Shen, L, Fernandez, AM, Stephan, C, Wang, J, Sikora, AG, Kazi, J, Frederick, MJ, Johnson, FM. Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma. Cancer Letters 625, 2025. e-Pub 2025. PMID: 40412794.
- Wang J. IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer. NPJ Precis Oncol, 2025. e-Pub 2025. PMID: 40715551.
- Wang J. KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer Cell, 2025. e-Pub 2025. PMID: 40645185.
- Wang J. Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer. J Immunother Cancer, 2025. e-Pub 2025. PMID: 40555561.
- Wang J. LMP7-Specific Inhibitor M3258 Modulates the Tumor Microenvironment of Triple-Negative Breast Cancer and Inflammatory Breast Cancer. Cancers (Basel), 2025. e-Pub 2025. PMID: 40507366.
- Wang J. Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. Cancer Res, 2025. e-Pub 2025. PMID: 40080526.
- Wang, Y, Meraz, I, Qudratullah, M, Kotagiri, S, Han, Y, Xi, Y, Wang, J, Akdemir, KC, Roth, JA, Lissanu, Y. Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. Cancer Research 85(11):1997-2013, 2025. e-Pub 2025. PMID: 40080526.
- Xie, X, Lee, J, Manyam, GC, Pearson, T, Walter-Bausch, G, Friese-Hamim, M, Zhao, S, Jabs, J, Manginelli, AA, Piske, N, Mrowiec, T, Wolf, CM, Kuntal, BS, Tripathy, D, Wang, J, Sanderson, MP, Ueno, NT. LMP7-Specific Inhibitor M3258 Modulates the Tumor Microenvironment of Triple-Negative Breast Cancer and Inflammatory Breast Cancer. Cancers 17(11), 2025. e-Pub 2025. PMID: 40507366.
- Wang J. BRAF(V600E)-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling. bioRxiv, 2025. e-Pub 2025. PMID: 40654950.
- Wang J. Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia. Blood Cancer J, 2025. e-Pub 2025. PMID: 40274779.
- Wang J. DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. iScience, 2025. e-Pub 2025. PMID: 40034862.
- Vailati Negrao, M, Paula, AG, Molkentine, D, Hover, LD, Nilsson, M, Vokes, N, Engstrom, LD, Calinisan, A, Briere, DM, Waters, L, Hallin, J, Diao, L, Altan, M, Blumenschein, GR, Skoulidis, F, Wang, J, Kopetz, S, Hong, DS, Gibbons, DL, Olson, P, Christensen, JG, Heymach, JV. Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clinical Cancer Research 31(6):1069-1081, 2025. e-Pub 2025. PMID: 39804166.
- Wang J. Avasimibe Abolishes the Efficacy of Fluvastatin for the Prevention of Cancer in a Spontaneous Mouse Model of Breast Cancer. Int J Mol Sci, 2025. e-Pub 2025. PMID: 40141147.
- Bhardwaj, A, Koh, A, Bhala, R, Sandhu, J, Ju, Z, Cando, LF, Wang, J, Bedrosian, I. Avasimibe Abolishes the Efficacy of Fluvastatin for the Prevention of Cancer in a Spontaneous Mouse Model of Breast Cancer. International journal of molecular sciences 26(6), 2025. e-Pub 2025. PMID: 40141147.
- Visal, TH, Bayraktar, R, Den Hollander, P, Attathikhun, MA, Zhou, T, Wang, J, Shen, L, Minciuna, CE, Chen, M, Barrientos Toro, E, Batra, H, Raso, G, Yang, F, Parra Cuentas, ER, Sahin, AA, Calin, GA, Mani, S. Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer. Cancer Research 85(5):894-911, 2025. e-Pub 2025. PMID: 39853244.
- Moreno Rueda, LY, Wang, H, Akagi, K, Dang, M, Vora, A, Qin, L, Lee, HC, Patel, K, Lin, P, Mery, D, Zhan, F, Shaughnessy, JD, Yi, Q, Song, Y, Jiang, B, Gillison, M, Thomas, SK, Weber, DM, Diao, L, Wang, J, Kuiatse, I, Manasanch, EE, Symer, DE, Orlowski, R. Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets. Cell Reports Medicine 6(2), 2025. e-Pub 2025. PMID: 39855192.
- Wang J. Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer. Mol Cancer, 2025. e-Pub 2025. PMID: 39955556.
- Meraz, I, Majidi, M, Song, R, Meng, F, Gao, L, Wang, Q, Wang, J, Shpall, E, Roth, JA. NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model. eLife 13, 2025. e-Pub 2025. PMID: 39932765.
- Wang J. Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins. Mol Cancer, 2025. e-Pub 2025. PMID: 39901247.
- Wang J. Amniotic fluid extracellular vesicle and cell-free RNA profiling reveals fetal adaptations in twin-twin transfusion syndrome. Am J Obstet Gynecol MFM, 2025. e-Pub 2025. PMID: 39993502.
- Wang J. Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer. Cancer Res, 2025. e-Pub 2025. PMID: 39853244.
- Wang J. Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets. Cell Rep Med, 2025. e-Pub 2025. PMID: 39855192.
- Wang J. Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial. Clin Cancer Res, 2025. e-Pub 2025. PMID: 39804166.
- Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Serrano AG, Tanimoto A, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Hamad SH, Cardnell RJ, Duarte A, Sahu M, Novegil VY, Weissman BE, Frumovitz M, Kalhor N, Solis Soto L, da Rocha P, Vokes N, Gibbons DL, Wang J, Heymach JV, Glisson B, Byers LA, Gay CM. YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities. Clin Cancer Res, 2024. e-Pub 2024. PMID: 39150543.
- Hu Y, Paris S, Sahoo N, Wang Q, Wang Q, Barsoumian HB, Huang A, Da Silva J, Bienassis C, Leyton CSK, Voss TA, Masrorpour F, Riad T, Leuschner C, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3. J Nanobiotechnology, 2024. e-Pub 2024. PMID: 39354474.
- Wang J. Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer. Cell Chem Biol, 2024. e-Pub 2024. PMID: 39378885.
- Wang J. Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3. J Nanobiotechnology, 2024. e-Pub 2024. PMID: 39378885.
- Kotagiri S, Blazanin N, Xi Y, Han Y, Qudratullah M, Liang X, Wang Y, Pandey P, Mazhar H, Lam TN, Singh AK, Wang J, Lissanu Y. Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer. Cell Chem Biol, 2024. e-Pub 2024. PMID: 39378885.
- Milman Krentsis I, Zheng Y, Rosen C, Shin SY, Blagdon C, Shoshan E, Qi Y, Wang J, Yadav SK, Bachar Lustig E, Shetzen E, Dickey BF, Karmouty-Quintana H, Reisner Y. Lung cell transplantation for pulmonary fibrosis. Sci Adv, 2024. e-Pub 2024. PMID: 39178253.
- Wang J. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer. J Exp Clin Cancer Res, 2024. e-Pub 2024.
- Wang J. YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities. Clin Cancer Res. 2024, 2024. e-Pub 2024. PMID: 39150543.
- Wang J. Neural landscape is associated with functional outcomes in irradiated patients with oropharyngeal squamous cell carcinoma. Sci Transl Med, 2024. e-Pub 2024. PMID: 39083586.
- Wang J. DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer. Clin Cancer Res, 2024. e-Pub 2024. PMID: 39211077.
- Wang J. DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer. bioRxiv, 2024. e-Pub 2024. PMID: 39211077.
- Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein LV, Welm AL, Dean DA, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm BE, Govindan R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona LG, Herlyn M, Davies MA, Shapiro GI, Fields RC, Trevino JG, Harrell JC, Doroshow JH, Chuang JH, Moscow JA. Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther, 2024. e-Pub 2024. PMID: 38641411.
- Rodriguez BL, Chen L, Li Y, Miao S, Peng DH, Fradette JJ, Diao L, Konen JM, Alvarez FRR, Solis LM, Yi X, Padhye A, Gibson LA, Ochieng JK, Zhou X, Wang J, Gibbons DL. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance. Front Immunol, 2024. e-Pub 2024. PMID: 37449205.
- Michikawa C, Gleber-Netto FO, Pickering CR, Rao X, Wang J, Sikora AG, Myers JN, Frederick MJ. Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer. Oral Oncol, 2024. e-Pub 2024. PMID: 38663156.
- Wang J. Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer. J Clin Invest, 2024. e-Pub 2024. PMID: 38662435.
- Lulla AR, Akli S, Karakas C, Caruso JA, Warma LD, Fowlkes NW, Rao X, Wang J, Hunt KK, Watowich SS, Keyomarsi K. Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis. Mol Cancer Ther, 2024. e-Pub 2024. PMID: 37796181.
- Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer, 2024. e-Pub 2024. PMID: 37985359.
- Zacharias NM, Segarra L, Akagi K, Fowlkes NW, Chen H, Alaniz A, de la Cerda C, Pesquera P, Xi Y, Wang J, Chahoud J, Lu X, Rao P, Martinez-Ferrer M, Pettaway CA. Transcriptomic, Proteomic, and Genomic Mutational Fraction Differences Based on HPV Status Observed in Patient-Derived Xenograft Models of Penile Squamous Cell Carcinoma. Cancers (Basel), 2024. e-Pub 2024. PMID: 38473423.
- Kim HK, Wang Q, Hwang SH, Dougherty PM, Wang J, Abdi S. Bardoxolone Methyl Ameliorates Chemotherapy-Induced Neuropathic Pain by Activation of Phosphorylated Nuclear Factor Erythroid 2-Related Factor 2 in the Dorsal Root Ganglia. Anesth Analg, 2024. e-Pub 2024. PMID: 38112490.
- Kim HK, Wang Q, Hwang SH, Dougherty PM, Wang J, Abdi S. Bardoxolone Methyl Ameliorates Chemotherapy-Induced Neuropathic Pain by Activation of Phosphorylated Nuclear Factor Erythroid 2-Related Factor 2 in the Dorsal Root Ganglia. Anesth Analg, 2024. e-Pub 2024. PMID: 38112490.
- Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horváth I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Van Loo P, Wang J, Wistuba II, Byers LA, Heymach JV. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell, 2024. e-Pub 2024. PMID: 38278149.
- Zhao M, Wang T, Gleber-Netto FO, Chen Z, McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, Wang Q, Tang X, Pathak S, Raso MG, Burks JK, Lin SY, Wang J, Multani AS, Pickering CR, Chen J, Myers JN, Zhou G. Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nat Commun 15(1):180, 2024. e-Pub 2024. PMID: 38167338.
- Zhao M, Wang T, Gleber-Netto FO, Chen Z, McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, Wang Q, Tang X, Pathak S, Raso MG, Burks JK, Lin SY, Wang J, Multani AS, Pickering CR, Chen J, Myers JN, Zhou G. Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nat Commun, 2024. e-Pub 2024. PMID: 38167338.
- Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets. JTO Clin Res Rep, 2023. e-Pub 2023. PMID: 38357092.
- Altan M, Li QZ, Wang Q, Vokes NI, Sheshadri A, Gao J, Zhu C, Tran HT, Gandhi S, Antonoff MB, Swisher S, Wang J, Byers LA, Abdel-Wahab N, Franco-Vega MC, Wang Y, Lee JJ, Zhang J, Heymach JV. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol, 2023. e-Pub 2023. PMID: 38152395.
- Singh SK, Wang Y, Habib A, Priyadarshini M, Kodavali CV, Chen A, Ma W, Wang J, Hameed NUF, Hu B, Fuller GN, Kulich SM, Amankulor N, Colen RR, Edwards LA, Zinn PO. TP53-PTEN-NF1 depletion in human brain organoids produces a glioma phenotype in vitro. Front Oncol, 2023. e-Pub 2023. PMID: 37881491.
- Wang J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, Singareeka Raghavendra A, Wang Y, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S, Tripathy D, Keyomarsi K. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers. Cancer Res, 2023. e-Pub 2023. PMID: 37384539.
- Wang J, Rodriguez BL, Wu H, Fradette JJ, Gibson L, Diao L, Wang J, Schmidt S, Wistuba II, Zhang J, Gibbons DL. Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer. J Clin Invest, 2023. e-Pub 2023. PMID: 37655662.
- Konen JM, Rodriguez BL, Wu H, Fradette JJ, Gibson L, Diao L, Wang J, Schmidt S, Wistuba II, Zhang J, Gibbons DL. Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer. J Clin Invest 133(17), 2023. e-Pub 2023. PMID: 37655662.
- Ramkumar K, Tanimoto A, Della Corte CM, Stewart CA, Wang Q, Shen L, Cardnell RJ, Wang J, Polanska UM, Andersen C, Saeh J, Pease JE, Travers J, Fabbri G, Gay CM, Urosevic J, Byers LA. Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer. Clin Cancer Res, 2023. e-Pub 2023. PMID: 37289191.
- Li Y, Zhu L, Ko CJ, Yang JY, Wang H, Manyam G, Wang J, Cheng X, Zhao S, Jie Z. TRAF3-EWSR1 signaling axis acts as a checkpoint on germinal center responses. J Exp Med 220(8), 2023. e-Pub 2023. PMID: 37097293.
- Amit M, Baruch E, Nagarajan P, Gleber-Netto F, Rao X, Xie T, Akhter S, Adewale A, Islam S, Mattson B, Ferrarotto R, Wong M, Davies M, Jindal S, Basu S, Harwood C, Leigh I, Ajami N, Futreal A, Castillo M, Gunarante P, Goepfert R, Khushalani N, Wang J, Watowich S, Calin G, Migden M, Vermeer P, D'Silva N, Yaniv D, Burks J, Gomez J, Dougherty P, Tsai K, Allison J, Sharma P, Wargo J, Myers J. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade. Res Sq, 2023. e-Pub 2023. PMID: 37503252.
- Qian Y, Galan-Cobo A, Guijarro I, Dang M, Molkentine D, Poteete A, Zhang F, Wang Q, Wang J, Parra E, Panda A, Fang J, Skoulidis F, Wistuba II, Verma S, Merghoub T, Wolchok JD, Wong KK, DeBerardinis RJ, Minna JD, Vokes NI, Meador CB, Gainor JF, Wang L, Reuben A, Heymach JV. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer Cell 41(7):1363-1380.e7, 2023. e-Pub 2023. PMID: 37327788.
- Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov 13(7):1556-1571, 2023. e-Pub 2023. PMID: 37068173.
- Marques-Piubelli ML, Seervai RNH, Mudaliar KM, Ma W, Milton DR, Wang J, Muhlbauer A, Parra ER, Solis LM, Nagarajan P, Speiser J, Hudgens C, Cho WC, Aung PP, Patel A, Pacha O, Nelson KC, Tetzlaff MT, Amaria RN, Torres-Cabala CA, Prieto VG, Wistuba II, Curry JL. Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of TH 1 T-cells. J Cutan Pathol 50(7):661-673, 2023. e-Pub 2023. PMID: 37150813.
- Rodriguez BL, Chen L, Li Y, Miao S, Peng DH, Fradette JJ, Diao L, Konen JM, Alvarez FRR, Solis LM, Yi X, Padhye A, Gibson LA, Ochieng JK, Zhou X, Wang J, Gibbons DL. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance. Front Immunol 14:1161869, 2023. e-Pub 2023. PMID: 37449205.
- Hu Y, Paris S, Sahoo N, Bertolet G, Wang Q, Wang Q, Barsoumian HB, Da Silva J, Huang A, Doss DJ, Pollock DP, Hsu E, Selene N, Leyton CSK, Voss TA, Masrorpour F, Ganjoo S, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight 8(12), 2023. e-Pub 2023. PMID: 37345658.
- Meraz IM, Majidi M, Fang B, Meng F, Gao L, Shao R, Song R, Li F, Lissanu Y, Chen H, Ha MJ, Wang Q, Wang J, Shpall E, Jung SY, Haderk F, Gui P, Riess JW, Olivas V, Bivona TG, Roth JA. 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol 6(1):509, 2023. e-Pub 2023. PMID: 37169941.
- Xi Y, Negrao MV, Akagi K, Xiao W, Jiang B, Warner SC, Dunn JD, Wang J, Symer DE, Gillison ML. Noninvasive genomic profiling of somatic mutations in oral cavity cancers. Oral Oncol 140:106372, 2023. e-Pub 2023. PMID: 37004423.
- Chen Z, Ho IL, Soeung M, Yen EY, Liu J, Yan L, Rose JL, Srinivasan S, Jiang S, Edward Chang Q, Feng N, Gay JP, Wang Q, Wang J, Lorenzi PL, Veillon LJ, Wei B, Weinstein JN, Deem AK, Gao S, Genovese G, Viale A, Yao W, Lyssiotis CA, Marszalek JR, Draetta GF, Ying H. Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis. Nat Commun 14(1):2194, 2023. e-Pub 2023. PMID: 37069167.
- Gouda MA, Duose DY, Lapin M, Zalles S, Huang HJ, Xi Y, Zheng X, Aldesoky AI, Alhanafy AM, Shehata MA, Wang J, Kopetz S, Meric-Bernstam F, Wistuba II, Luthra R, Janku F. Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures. Oncologist 28(4):368-372, 2023. e-Pub 2023. PMID: 36200910.
- Patel SA, Nilsson MB, Yang Y, Le X, Tran HT, Elamin YY, Yu X, Zhang F, Poteete A, Ren X, Shen L, Wang J, Moghaddam SJ, Cascone T, Curran M, Gibbons DL, Heymach JV. IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clin Cancer Res 29(7):1292-1304, 2023. e-Pub 2023. PMID: 36595561.
- Osman AA, Arslan E, Bartels M, Michikawa C, Lindemann A, Tomczak K, Yu W, Sandulache V, Ma W, Shen L, Wang J, Singh AK, Frederick MJ, Spencer ND, Kovacs J, Heffernan T, Symmans WF, Rai K, Myers JN. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 29(7):1344-1359, 2023. e-Pub 2023. PMID: 36689560.
- Hernandez S, Das P, Holliday EB, Shen L, Lu W, Johnson B, Messick CA, Taniguchi CM, Skibber J, Ludmir EB, You YN, Smith GL, Bednarski B, Kostousov L, Koay EJ, Minsky BD, Tillman M, Portier S, Eng C, Koong AC, Chang GJ, Foo WC, Wang J, Soto LS, Morris VK. Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer. Cancers (Basel) 15(6), 2023. e-Pub 2023. PMID: 36980587.
- Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
- Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, Zhang M, Robichaux JP, Shi C, Pfeil AN, Tran H, Gibbons DL, Bock J, Wang J, Minna JD, Kobayashi SS, Le X, Heymach JV. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell 41(2):340-355.e6, 2023. e-Pub 2023. PMID: 36787696.
- Zhao Q, Hu J, Kong L, Jiang S, Tian X, Wang J, Hashizume R, Jia Z, Fowlkes NW, Yan J, Xia X, Yi SF, Dao LH, Masopust D, Heimberger AB, Li S. FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells. Nat Commun 14(1):735, 2023. e-Pub 2023. PMID: 36759517.
- Liu TW, Gammon ST, Yang P, Ma W, Wang J, Piwnica-Worms D. Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma. J Immunother Cancer 11(2), 2023. e-Pub 2023. PMID: 36805920.
- Altan M, Li QZ, Wang Q, Vokes NI, Sheshadri A, Gao J, Zhu C, Tran HT, Gandhi S, Antonoff MB, Swisher S, Wang J, Byers LA, Abdel-Wahab N, Franco-Vega MC, Wang Y, Lee JJ, Zhang J, Heymach JV. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol 14:1322818, 2023. e-Pub 2023. PMID: 38152395.
- Wang X, Semba T, Manyam GC, Wang J, Shao S, Bertucci F, Finetti P, Krishnamurthy S, Phi LTH, Pearson T, Van Laere SJ, Burks JK, Cohen EN, Reuben JM, Yang F, Min H, Navin N, Trinh VN, Iwase T, Batra H, Shen Y, Zhang X, Tripathy D, Ueno NT. EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. Sci Adv 8(50):eabn7983, 2022. e-Pub 2022. PMID: 36525493.
- Shah, P, Sambandam, V, Fernandez, AM, Zhao, H, Mazumdar, T, Shen, L, Wang, Q, Ahmed, KM, Ghosh, S, Frederick, MJ, Wang, J, Johnson, FM. Sustained Aurora Kinase B Expression Confers Resistance to PI3K Inhibition in Head and Neck Squamous Cell Carcinoma. Cancer Research 82(23):4444-4456, 2022. e-Pub 2022. PMID: 36169922.
- Della Corte CM, Ciaramella V, Ramkumar K, Vicidomini G, Fiorelli A, Nardone V, Cappabianca S, Cozzolino I, Zito Marino F, Di Guida G, Wang Q, Cardnell R, Gay CM, Ciardiello D, Martinelli E, Troiani T, Martini G, Napolitano S, Wang J, Byers LA, Ciardiello F, Morgillo F. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. J Transl Med 20(1):541, 2022. e-Pub 2022. PMID: 36419183.
- Yu X, Zhang Y, Xiong S, McDaniel JM, Sun C, Chau GP, Gencel-Augusto J, Chachad D, Morrissey RL, Rao X, Wang J, Lozano G. Omics analyses of a somatic Trp53R245W/+ breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling. Proc Natl Acad Sci U S A 119(45):e2210618119, 2022. e-Pub 2022. PMID: 36322759.
- Ghosh S, Mazumdar T, Xu W, Powell RT, Stephan C, Shen L, Shah PA, Pickering CR, Myers JN, Wang J, Frederick MJ, Johnson FM. Combined TRIP13 and Aurora kinase inhibition induces apoptosis in human papillomavirus-driven cancers. Clin Cancer Res, 2022. e-Pub 2022. PMID: 35972731.
- Chrisikos TT, Zhou Y, Kahn LM, Patel B, Denne NL, Brooks A, Shen L, Wang J, Watowich SS. STAT3 Inhibits Autocrine IFN Signaling in Type I Conventional Dendritic Cells. J Immunol, 2022. e-Pub 2022. PMID: 36038291.
- Yang Q, Hu J, Jia Z, Wang Q, Wang J, Dao LH, Zhang W, Zhang S, Xia X, Gorlick R, Li S. Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma. Clin Cancer Res 28(17):3862-3873, 2022. e-Pub 2022. PMID: 35727602.
- Lyu Y, Guan Y, Deliu L, Humphrey E, Frontera JK, Yang YJ, Zamler D, Kim KH, Mohanty V, Jin K, Mohanty V, Liu V, Dou J, Veillon LJ, Kumar SV, Lorenzi PL, Chen Y, McAndrews KM, Grivennikov S, Song X, Zhang J, Xi Y, Wang J, Chen K, Nagarajan P, Ge Y. KLF5 governs sphingolipid metabolism and barrier function of the skin. Genes Dev, 2022. e-Pub 2022. PMID: 36008138.
- Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. Br J Cancer, 2022. e-Pub 2022. PMID: 35440668.
- Huang L, Wang J, Fang B, Meric-Bernstam F, Roth JA, Ha MJ. CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts. Sci Rep 12(1):12984, 2022. e-Pub 2022. PMID: 35906256.
- Shi Y, Xie T, Wang B, Wang R, Cai Y, Yuan B, Gleber-Netto FO, Tian X, Rodriguez-Rosario AE, Osman AA, Wang J, Pickering CR, Ren X, Sikora AG, Myers JN, Rangel R. Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma. Commun Biol 5(1):757, 2022. e-Pub 2022. PMID: 35902768.
- Bhardwaj A, Rojo RD, Ju Z, Koh A, Tachibana K, Wang J, Bedrosian I. The molecular heterogeneity of the precancerous breast affects drug efficacy. Sci Rep 12(1):12590, 2022. e-Pub 2022. PMID: 35869155.
- Yoon, EC, Wang, G, Parkinson, B, Huo, L, Peng, Y, Wang, J, Salisbury, T, Wu, Y, Chen, H, Albarracin, C, Resetkova, E, Middleton, LP, Krishnamurthy, S, Gan, Q, Sun, H, Huang, X, Shen, T, Chen, W, Parwani, AV, Sahin, AA, Li, Z, Ding, Q. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Human Pathology 125:97-107, 2022. e-Pub 2022. PMID: 35413381.
- Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, Team I. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform 6:e2200040, 2022. e-Pub 2022. PMID: 35944232.
- Pantaleón García J, Kulkarni VV, Reese TC, Wali S, Wase SJ, Zhang J, Singh R, Caetano MS, Kadara H, Moghaddam SJ, Johnson FM, Wang J, Wang Y, Evans SE. OBIF: an omics-based interaction framework to reveal molecular drivers of synergy. NAR Genom Bioinform 4(2):lqac028, 2022. e-Pub 2022. PMID: 35387383.
- Ju Z, Thomas TN, Chiu YJ, Yamanouchi S, Yoshida Y, Abe JI, Takahashi A, Wang J, Fujiwara K, Hada M. Adaptation and Changes in Actin Dynamics and Cell Motility as Early Responses of Cultured Mammalian Cells to Altered Gravitational Vector. Int J Mol Sci 23(11), 2022. e-Pub 2022. PMID: 35682810.
- Liu Y, Deguchi Y, Wei D, Liu F, Moussalli MJ, Deguchi E, Li D, Wang H, Valentin LA, Colby JK, Wang J, Zheng X, Ying H, Gagea M, Ji B, Shi J, Yao JC, Zuo X, Shureiqi I. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ. Nat Commun 13(1):2665, 2022. e-Pub 2022. PMID: 35562376.
- Kundu ST, Rodriguez BL, Gibson LA, Warner AN, Perez MG, Bajaj R, Fradette JJ, Class CA, Solis LM, Rojas Alvarez FR, Wistuba II, Diao L, Chen F, Sachdeva M, Wang J, Kirsch DG, Creighton CJ, Gibbons DL. The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response. Genes Dev 36(9-10):582-600, 2022. e-Pub 2022. PMID: 35654454.
- Sun X, Zhai J, Sun B, Parra ER, Jiang M, Ma W, Wang J, Kang AM, Kannan K, Pandurengan R, Zhang S, Solis LM, Haymaker CL, Raso MG, Mendoza Perez J, Sahin AA, Wistuba II, Yam C, Litton JK, Yang F. Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Mod Pathol, 2022. e-Pub 2022. PMID: 34839351.
- Le X, Gleber-Netto FO, Rubin ML, Qing Y, Du R, Kies M, Blumenschein G, Lu C, Johnson FM, Bell D, Lewis J, Zhang J, Feng L, Wilson K, Marcelo-Lewis K, Wang J, Ginsberg L, Gillison M, Lee JJ, Meric-Bernstam F, Mills GB, William WN, Myers JN, Pickering CR. Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res, 2022. e-Pub 2022. PMID: 35443062.
- Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
- Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther 7(1):110, 2022. e-Pub 2022. PMID: 35365596.
- Della Corte CM, Fasano M, Ciaramella V, Cimmino F, Cardnell R, Gay CM, Ramkumar K, Diao L, Di Liello R, Viscardi G, Famiglietti V, Ciardiello D, Martini G, Napolitano S, Tuccillo C, Troiani T, Martinelli E, Wang J, Byers L, Morgillo F, Ciardiello F. Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. J Exp Clin Cancer Res 41(1):109, 2022. e-Pub 2022. PMID: 35346313.
- Bhardwaj A, Embury MD, Ju Z, Wang J, Bedrosian I. Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer. BMC Cancer 22(1):282, 2022. e-Pub 2022. PMID: 35296281.
- Wang, J, Wang, W, Sun, H, Huo, L, Wu, Y, Chen, H, Gan, Q, Meis, JM, Maloney, N, Lazar, A, Yoon, EC, Albarracin, C, Krishnamurthy, S, Middleton, LP, Resetkova, E, Yu, W, Tan, D, Lu, W, Solis Soto, LM, Wang, S, Wistuba, II, Parwani, AV, Prieto, V, Sahin, AA, Li, Z, Ding, Q. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Human Pathology 121:73-80, 2022. e-Pub 2022. PMID: 35063444.
- Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
- Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther 7(1):51, 2022. e-Pub 2022. PMID: 35185150.
- Zhang X, Zhang R, Ren C, Xu Y, Wu S, Meng C, Pataer A, Song X, Zhang J, Yao Y, He H, Chen H, Ma W, Wang J, Meric-Bernstam F, Champlin RE, Heymach JV, Rooney CM, Swisher SG, Vaporciyan AA, Roth JA, You MJ, Wang M, Fang B. Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv 6(3):891-901, 2022. e-Pub 2022. PMID: 34861697.
- Galan-Cobo A, Stellrecht CM, Yilmaz E, Yang C, Qian Y, Qu X, Akhter I, Ayres ML, Fan Y, Tong P, Diao L, Ding J, Giri U, Gudikote J, Nilsson M, Wierda WG, Wang J, Skoulidis F, Minna JD, Gandhi V, Heymach JV. Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Mol Cancer Res, 2022. e-Pub 2022. PMID: 34654720.
- Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q, Barrese TZ, Massarelli E, William W, Johnson FM, Ferrarotto R, Wistuba I, Coarfa C, Lee J, Wang J, Melief CJM, Curran MA, Glisson BS. ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer 10(2), 2022. e-Pub 2022. PMID: 35193933.
- Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam F. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep 12(1):1248, 2022. e-Pub 2022. PMID: 35075200.
- Sezen D, Barsoumian HB, He K, Hu Y, Wang Q, Abana CO, Puebla-Osorio N, Hsu EY, Wasley M, Masrorpour F, Wang J, Cortez MA, Welsh JW. Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Front Immunol 13:984318, 2022. e-Pub 2022. PMID: 36275767.
- Hu Y, Paris S, Bertolet G, Barsoumian HB, Wang Q, Da Silva J, Patel NB, Nguyen N, Doss DJ, Huang A, Hsu E, Leyton CSK, Voss TA, Masrorpour F, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Front Immunol 13:1022011, 2022. e-Pub 2022. PMID: 36405757.
- Callahan SC, Kochat V, Liu Z, Raman AT, Divenko M, Schulz J, Terranova CJ, Ghosh AK, Tang M, Johnson FM, Wang J, Skinner HD, Pickering CR, Myers JN, Rai K. High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma. Front Cell Dev Biol 10:936168, 2022. e-Pub 2022. PMID: 35927986.
- Patel SA, Herynk MH, Cascone T, Saigal B, Nilsson MB, Tran H, Ramachandran S, Diao L, Wang J, Le X, Minna J, Wistuba II, Heymach JV. Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. J Thorac Oncol, 2021. e-Pub 2021. PMID: 34311109.
- Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, Chen Y, Wu M, Behrens C, Chow CW, Pham HHN, Fukuoka J, Wu J, Parra ER, Little LD, Gumbs C, Song X, Wu CJ, Diao L, Wang Q, Cardnell R, Zhang J, Wang J, Le X, Gibbons DL, Heymach JV, Jack Lee J, William WN, Cheng C, Glisson B, Wistuba I, Andrew Futreal P, Thomas RK, Reuben A, Byers LA, Zhang J. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun 12(1):6655, 2021. e-Pub 2021. PMID: 34789716.
- Banerjee P, Xiao GY, Tan X, Zheng VJ, Shi L, Rabassedas MNB, Guo HF, Liu X, Yu J, Diao L, Wang J, Russell WK, Roszik J, Creighton CJ, Kurie JM. The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells. Nat Commun 12(1):6354, 2021. e-Pub 2021. PMID: 34732702.
- Kumar M, Molkentine D, Molkentine J, Bridges K, Xie T, Yang L, Hefner A, Gao M, Bahri R, Dhawan A, Frederick MJ, Seth S, Abdelhakiem M, Beadle BM, Johnson F, Wang J, Shen L, Heffernan T, Sheth A, Ferris RL, Myers JN, Pickering CR, Skinner HD. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun 12(1):6340, 2021. e-Pub 2021. PMID: 34732714.
- McGuire MH, Dasari SK, Yao H, Wen Y, Mangala LS, Bayraktar E, Ma W, Ivan C, Shoshan E, Wu SY, Jonasch E, Bar-Eli M, Wang J, Baggerly KA, Sood AK. Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling. Mol Cancer Res, 2021. e-Pub 2021. PMID: 34348992.
- Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology. J Thorac Oncol, 2021. e-Pub 2021. PMID: 34274504.
- Gudikote JP, Cascone T, Poteete A, Sitthideatphaiboon P, Wu Q, Morikawa N, Zhang F, Peng S, Tong P, Li L, Shen L, Nilsson M, Jones P, Sulman EP, Wang J, Bourdon JC, Johnson FM, Heymach JV. Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. J Biol Chem:101163, 2021. e-Pub 2021. PMID: 34481841.
- Cargill KR, Stewart CA, Park EM, Ramkumar K, Gay CM, Cardnell RJ, Wang Q, Diao L, Shen L, Fan YH, Chan WK, Lorenzi PL, Oliver TG, Wang J, Byers LA. Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. Cancer Metab 9(1):33, 2021. e-Pub 2021. PMID: 34556188.
- Padhye A, Konen JM, Rodriguez BL, Fradette JJ, Ochieng JK, Diao L, Wang J, Lu W, Solis LS, Batra H, Raso MG, Peoples MD, Minelli R, Carugo A, Bristow CA, Gibbons DL. Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer. JCI Insight 6(17), 2021. e-Pub 2021. PMID: 34309585.
- Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JV. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597(7878):732-737, 2021. e-Pub 2021. PMID: 34526717.
- Aslan B, Kismali G, Chen LS, Iles LR, Mahendra M, Peoples M, Gagea M, Fowlkes NW, Zheng X, Wang J, Vellano CP, Marszalek JR, Bertilaccio MTS, Gandhi V. Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL. Blood Adv 5(16):3134-3146, 2021. e-Pub 2021. PMID: 34424317.
- Shi L, Tan X, Liu X, Yu J, Bota-Rabassedas N, Niu Y, Luo J, Xi Y, Zong C, Creighton CJ, Glenn JS, Wang J, Kurie JM. Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3-amplified lung adenocarcinoma cells. Proc Natl Acad Sci U S A 118(25), 2021. e-Pub 2021. PMID: 34155143.
- Khan IM, Gjuka D, Jiao J, Song X, Wang Y, Wang J, Wei P, El-Serag HB, Marrero JA, Beretta L. A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila), 2021. e-Pub 2021. PMID: 33685927.
- Adam L, Wszolek MF, Liu CG, Wang J, Diao L, Zien A, Zhang JD, Jackson D, Dinney CP. Plasma microRNA profiles for bladder cancer detection. Urol Oncol, 2021. e-Pub 2021. PMID: 22863868.
- Lulla AR, Akli S, Karakas C, Ha MJ, Fowlkes NW, Mitani Y, Bui T, Wang J, Rao X, Hunt KK, Meijer L, El-Naggar AK, Keyomarsi K. LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis 10(5):40, 2021. e-Pub 2021. PMID: 33990543.
- Peng DH, Rodriguez BL, Diao L, Gaudreau PO, Padhye A, Konen JM, Ochieng JK, Class CA, Fradette JJ, Gibson L, Chen L, Wang J, Byers LA, Gibbons DL. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nat Commun 12(1):2606, 2021. e-Pub 2021. PMID: 33972557.
- Bota-Rabassedas N, Banerjee P, Niu Y, Cao W, Luo J, Xi Y, Tan X, Sheng K, Ahn YH, Lee S, Parra ER, Rodriguez-Canales J, Albritton J, Weiger M, Liu X, Guo HF, Yu J, Rodriguez BL, Firestone JJA, Mino B, Creighton CJ, Solis LM, Villalobos P, Raso MG, Sazer DW, Gibbons DL, Russell WK, Longmore GD, Wistuba II, Wang J, Chapman HA, Miller JS, Zong C, Kurie JM. Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. Cell Rep 35(3):109009, 2021. e-Pub 2021. PMID: 33882319.
- Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target. J Thorac Oncol 16(4):583-600, 2021. e-Pub 2021. PMID: 33388477.
- Gu M, Zhou X, Sohn JH, Zhu L, Jie Z, Yang JY, Zheng X, Xie X, Yang J, Shi Y, Brightbill HD, Kim JB, Wang J, Cheng X, Sun SC. Author Correction: NF-κB-inducing kinase maintains T cell metabolic fitness in antitumor immunity. Nat Immunol 22(4):530, 2021. e-Pub 2021. PMID: 33574621.
- Lam VK, Zhang J, Wu CC, Tran HT, Li L, Diao L, Wang J, Rinsurongkawong W, Raymond VM, Lanman RB, Lewis J, Roarty EB, Roth J, Swisher S, Lee JJ, Gibbons DL, Papadimitrakopoulou VA, Heymach JV. Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. J Thorac Oncol 16(4):601-609, 2021. e-Pub 2021. PMID: 33388476.
- Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39(3):346-360.e7, 2021. e-Pub 2021. PMID: 33482121.
- Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, Fowlkes NW, Fradette JJ, Peng DH, Cardnell RJ, Kovacs JJ, Wang J, Byers LA, Gibbons DL. Dual inhibition of MEK and AXL targets tumor cell heterogeneity and prevents resistant outgrowth mediated by the epithelial-to-mesenchymal transition in NSCLC. Cancer Res 81(5):1398-1412, 2021. e-Pub 2021. PMID: 33402388.
- Monteiro de Oliveira Novaes JA, Hirz T, Guijarro I, Nilsson M, Pisegna MA, Poteete A, Barsoumian HB, Fradette JJ, Chen LN, Gibbons DL, Tian X, Wang J, Myers JN, McArthur MJ, Bell D, William WN, Heymach JV. Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. Cancer Prev Res (Phila), 2021. e-Pub 2021. PMID: 33277316.
- Kawakami M, Mustachio LM, Chen Y, Chen Z, Liu X, Wei CH, Roszik J, Kittai AS, Danilov AV, Zhang X, Fang B, Wang J, Heymach JV, Tyutyunyk-Massey L, Freemantle SJ, Kurie JM, Liu X, Dmitrovsky E. A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis and Metastasis in Aneuploid Cancers. Mol Cancer Ther, 2021. e-Pub 2021. PMID: 33277443.
- Ramkumar K, Stewart CA, Cargill KR, Della Corte CM, Wang Q, Shen L, Diao L, Cardnell RJ, Peng DH, Rodriguez BL, Fan YH, Heymach JV, Wang J, Gay CM, Gibbons DL, Byers LA. AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Mol Cancer Res, 2021. e-Pub 2021. PMID: 33172976.
- Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever EM, Wescott EC, Johnson DB, Whitley E, Lehmann L, Courand PY, Mancuso JJ, Himmel LE, Lebrun-Vignes B, Wleklinski MJ, Knollmann BC, Srinivasan J, Li Y, Atolagbe OT, Rao X, Zhao Y, Wang J, Ehrlich LIR, Sharma P, Salem JE, Balko JM, Moslehi JJ, Allison JP. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discov, 2021. e-Pub 2021. PMID: 33257470.
- Nilsson MB, Robichaux J, Herynk MH, Cascone T, Le X, Elamin Y, Patel S, Zhang F, Xu L, Hu L, Diao L, Shen L, He J, Yu X, Nikolinakos P, Saintigny P, Fang B, Girard L, Wang J, Minna JD, Wistuba II, Heymach JV. Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. J Thorac Oncol 16(3):439-451, 2021. e-Pub 2021. PMID: 33309987.
- Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, Mendt M, Kerbauy LN, Banerjee PP, Shanley M, Imahashi N, Li L, FLWI L, Fathi M, Rezvan A, Mohanty V, Shen Y, Shaim H, Lu J, Ozcan G, Ensley E, Kaplan M, Nandivada V, Bdiwi M, Acharya S, Xi Y, Wan X, Mak D, Liu E, Jiang XR, Ang S, Muniz-Feliciano L, Li Y, Wang J, Kordasti S, Petrov N, Varadarajan N, Marin D, Brunetti L, Skinner RJ, Lyu S, Silva L, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Li H, Fowlkes NW, Chen K, Konopleva M, Champlin RE, Shpall EJ, Rezvani K. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137(5):624-636, 2021. e-Pub 2021. PMID: 32902645.
- Gu M, Zhou X, Sohn JH, Zhu L, Jie Z, Yang JY, Zheng X, Xie X, Yang J, Shi Y, Brightbill HD, Kim JB, Wang J, Cheng X, Sun SC. NF-κB-inducing kinase maintains T cell metabolic fitness in antitumor immunity. Nat Immunol 22(2):193-204, 2021. e-Pub 2021. PMID: 33398181.
- Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, Consortium P, Consortium E. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 53(1):86-99, 2021. e-Pub 2021. PMID: 33414553.
- Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets TV, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara HN, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG, Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol 16(1):127-139, 2021. e-Pub 2021. PMID: 33096269.
- Mendt M, Daher M, Basar R, Shanley M, Kumar B, Wei Inng FL, Acharya S, Shaim H, Fowlkes N, Tran JP, Gokdemir E, Uprety N, Nunez-Cortes AK, Ensley E, Mai T, Kerbauy LN, Melo-Garcia L, Lin P, Shen Y, Mohanty V, Lu J, Li S, Nandivada V, Wang J, Banerjee P, Reyes-Silva F, Liu E, Ang S, Gilbert A, Li Y, Wan X, Gu J, Zhao M, Baran N, Muniz-Feliciano L, Wilson J, Kaur I, Gagea M, Konopleva M, Marin D, Tang G, Chen K, Champlin R, Rezvani K, Shpall EJ. Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD. Front Immunol 12:631353, 2021. e-Pub 2021. PMID: 34017325.
- Batth IS, Dao L, Satelli A, Mitra A, Yi S, Noh H, Li H, Brownlee Z, Zhou S, Bond J, Wang J, Gill J, Sholler GS, Li S. Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients. Int J Cancer, 2020. e-Pub 2020. PMID: 32506485.
- Khoury JD, Tashakori M, Yang H, Loghavi S, Wang Y, Wang J, Piya S, Borthakur G. Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation. Cancers (Basel) 12(12), 2020. e-Pub 2020. PMID: 33255818.
- Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol 21(1):271, 2020. e-Pub 2020. PMID: 33148332.
- Yang JY, Jie Z, Mathews A, Zhou X, Li Y, Gu M, Xie X, Ko CJ, Cheng X, Qi Y, Estrella JS, Wang J, Sun SC. Intestinal Epithelial TBK1 Prevents Differentiation of T-helper 17 Cells and Tumorigenesis in Mice. Gastroenterology, 2020. e-Pub 2020. PMID: 32745468.
- Jaiswal AR, Liu AJ, Pudakalakatti S, Dutta P, Jayaprakash P, Bartkowiak T, Ager CR, Wang ZQ, Reuben A, Cooper ZA, Ivan C, Ju Z, Nwajei F, Wang J, Davies MA, Davis RE, Wargo JA, Bhattacharya PK, Hong DS, Curran MA. Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunol Res 8(11):1365-1380, 2020. e-Pub 2020. PMID: 32917656.
- Gleber-Netto FO, Neskey D, Costa AFM, Kataria P, Rao X, Wang J, Kowalski LP, Pickering CR, Dias-Neto E, Myers JN. Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma. Cancer, 2020. e-Pub 2020. PMID: 32797678.
- Dai Y, Luo W, Yue X, Ma W, Wang J, Chang J. Identification and characterization of a new isoform of small GTPase RhoE. Commun Biol 3(1):572, 2020. e-Pub 2020. PMID: 33060740.
- Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, Wei Y, Chapman HA, Yamauchi M, Behrens C, Raso G, Soto LMS, Cuentes ERP, Wistuba II, Kurie JM, Gibbons DL. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun 11(1):4520, 2020. e-Pub 2020. PMID: 32908154.
- Rao Y, Gammon S, Zacharias NM, Liu T, Salzillo T, Xi Y, Wang J, Bhattacharya P, Piwnica-Worms D. Hyperpolarized [1-13C]pyruvate-to-[1-13C]lactate conversion is rate-limited by monocarboxylate transporter-1 in the plasma membrane. Proc Natl Acad Sci U S A 117(36):22378-22389, 2020. e-Pub 2020. PMID: 32839325.
- Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, Diao L, Xi Y, Tong P, Shen L, Hofstad M, Kawakami M, Le X, Liu X, Fan Y, Poteete A, Hu L, Negrao MV, Tran H, Dmitrovsky E, Peng D, Gibbons DL, Wang J, Heymach JV. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med 12(559), 2020. e-Pub 2020. PMID: 32878980.
- Corsini EM, Wang Q, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Reuben A, Vasquez ME, Bernatchez C, Wang J, Cascone T, Zhang J, Heymach JV, Gibbons DL, Haymaker CL, Sepesi B. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer 146:303-309, 2020. e-Pub 2020. PMID: 32619781.
- Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother 69(8):1519-1534, 2020. e-Pub 2020. PMID: 32300858.
- Batth IS, Meng Q, Wang Q, Torres KE, Burks J, Wang J, Gorlick R, Li S. Rare osteosarcoma cell subpopulation protein array and profiling using imaging mass cytometry and bioinformatics analysis. BMC Cancer 20(1):715, 2020. e-Pub 2020. PMID: 32736533.
- Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Wistuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. J Thorac Oncol 15(5):777-791, 2020. e-Pub 2020. PMID: 32068166.
- Ju Z, Bhardwaj A, Embury MD, Singh H, Gunaratne PH, Bedrosian I, Wang J. Integrative Analyses of Multilevel Omics Reveal Preneoplastic Breast to Possess a Molecular Landscape That is Globally Shared with Invasive Basal-Like Breast Cancer (Running Title: Molecular Landscape of Basal-Like Breast Cancer Progression). Cancers (Basel) 12(3), 2020. e-Pub 2020. PMID: 32204397.
- Chen Y, Fang R, Yue C, Chang G, Li P, Guo Q, Wang J, Zhou A, Zhang S, Fuller GN, Shi X, Huang S. Wnt-Induced Stabilization of KDM4C Is Required for Wnt/β-Catenin Target Gene Expression and Glioblastoma Tumorigenesis. Cancer Res 80(5):1049-1063, 2020. e-Pub 2020. PMID: 31888886.
- Nelson DB, Mitchell KG, Wang J, Fujimoto J, Godoy M, Behrens C, Zheng X, Zhang J, Sepesi B, Vaporciyan AA, Hofstetter WL, Mehran RJ, Rice DC, Walsh GL, Swisher SG, Moran CA, Kalhor N, Weissferdt A, Wistuba II, Roth JA, Antonoff MB. Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. J Thorac Dis 12(3):329-337, 2020. e-Pub 2020. PMID: 32274099.
- Amit M, Takahashi H, Dragomir MP, Lindemann A, Gleber-Netto FO, Pickering CR, Anfossi S, Osman AA, Cai Y, Wang R, Knutsen E, Shimizu M, Ivan C, Rao X, Wang J, Silverman DA, Tam S, Zhao M, Caulin C, Zinger A, Tasciotti E, Dougherty PM, El-Naggar A, Calin GA, Myers JN. Loss of p53 drives neuron reprogramming in head and neck cancer. Nature 578(7795):449-454, 2020. e-Pub 2020. PMID: 32051587.
- Stewart A, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nature Cancer, 2020. e-Pub 2020.
- Pataer A, Ozpolat B, Shao R, Cashman NR, Plotkin SS, Samuel CE, Lin SH, Kabil NN, Wang J, Majidi M, Fang B, Roth JA, Vaporciyan AA, Wistuba II, Hung MC, Swisher SG. Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene 39(4):801-813, 2020. e-Pub 2020. PMID: 31554935.
- Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A, Wu S, Meng QH, Ha MJ, Morris J, Xi Y, Wang J, Zhang J, Gibbons DL, Heymach JV, Meric-Bernstam F, Minna J, Swisher SG, Roth JA, Fang B. KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res 10(12):4464-4475, 2020. e-Pub 2020. PMID: 33415011.
- Mak MP, Pasini FS, Diao L, Garcia FOT, Takahashi TK, Nakazato D, Martins RE, Almeida CM, Kulcsar MAV, Lamounier VA, Nunes EM, de Souza IC, Garcia MRT, Amadio AV, Siqueira SAC, Snitcovsky IML, Sichero L, Wang J, de Castro G. Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers. Ecancermedicalscience 14:1155, 2020. e-Pub 2020. PMID: 33574900.
- Veeranki OL, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, Kim TB, Wang J, Lang W, Mino B, Solis L, Kingsley C, Norton W, Tailor R, Wu JY, Krishnan S, Lin SH, Blum M, Hofstetter W, Ajani J, Kopetz S, Maru D. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech 12(12), 2019. e-Pub 2019. PMID: 31732509.
- Massarelli E, Lam VK, Parra ER, Rodriguez-Canales J, Behrens C, Diao L, Wang J, Blando J, Byers LA, Yanamandra N, Brett S, Morley P, Sharma P, Allison J, Wistuba II, Heymach JV. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. J Immunother Cancer 7(1):351, 2019. e-Pub 2019. PMID: 31843013.
- Li L, Chen H, Marin D, Xi Y, Miao Q, Lv J, Banerjee PP, Shaim H, Daher M, Basar R, Imahashi N, Jimenez J, Hu B, Mehta RS, Kerbauy LN, Kaplan M, Mendt M, Ozcan G, Gokdemir E, Hernandez Sanabria M, Li Y, Chen K, Wang J, Muniz-Feliciano L, Zhao WL, Champlin RE, Shpall EJ, Rezvani K. A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv 3(23):4117-4130, 2019. e-Pub 2019. PMID: 31821460.
- Sen T, Della Corte CM, Milutinovic S, Cardnell RJ, Diao L, Ramkumar K, Gay CM, Stewart CA, Fan Y, Shen L, Hansen RJ, Strouse B, Hedrick MP, Hassig CA, Heymach JV, Wang J, Byers LA. Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer. J Thorac Oncol 14(12):2152-2163, 2019. e-Pub 2019. PMID: 31470128.
- Mesmar F, Dai B, Ibrahim A, Hases L, Jafferali MH, Jose Augustine J, DiLorenzo S, Kang Y, Zhao Y, Wang J, Kim M, Lin CY, Berkenstam A, Fleming J, Williams C. Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling. Cancer Med 8(18):7705-7719, 2019. e-Pub 2019. PMID: 31568691.
- Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Jeffrey Medeiros L, Karam JA, Tamboli P, Sircar K. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol, 2019. e-Pub 2019. PMID: 31231128.
- Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 36(4):444-457.e7, 2019. e-Pub 2019. PMID: 31588020.
- Lindemann A, Patel AA, Silver NL, Tang L, Liu Z, Wang L, Tanaka N, Rao X, Takahashi H, Maduka NK, Zhao M, Chen TC, Liu W, Gao M, Wang J, Frank SJ, Hittelman WN, Mills GB, Myers JN, Osman AA. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. Clin Cancer Res 25(18):5650-5662, 2019. e-Pub 2019. PMID: 31308060.
- Kadara H, Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Davies GE, Kalhor N, Moran C, El-Zein R, Mehran R, Swisher SG, Wang J, Zhang J, Fujimoto J, Fowler J, Heymach JV, Dubinett S, Spira AE, Ehli EA, Wistuba II, Scheet P. Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. Am J Respir Crit Care Med, 2019. e-Pub 2019. PMID: 30896962.
- Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JP, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin Cancer Res, 2019. e-Pub 2019. PMID: 30867218.
- Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis F, DeBerardinis RJ, Minna JD, Heymach JV. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. Cancer Res 79(13):3251-3267, 2019. e-Pub 2019. PMID: 31040157.
- Zuo X, Deguchi Y, Xu W, Liu Y, Li HS, Wei D, Tian R, Chen W, Xu M, Yang Y, Gao S, Jaoude JC, Liu F, Chrieki SP, Moussalli MJ, Gagea M, Sebastian MM, Zheng X, Tan D, Broaddus R, Wang J, Ajami NJ, Swennes AG, Watowich SS, Shureiqi I. PPARD and Interferon gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice. Gastroenterology, 2019. e-Pub 2019. PMID: 30885780.
- Zhou X, Yu J, Cheng X, Zhao B, Manyam GC, Zhang L, Schluns K, Li P, Wang J, Sun SC. The deubiquitinase Otub1 controls the activation of CD8+ T cells and NK cells by regulating IL-15-mediated priming. Nat Immunol 20(7):879-889, 2019. e-Pub 2019. PMID: 31182807.
- Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA, Yin CC, Konopleva M, Zheng X, Wang J, Tang Z, Medeiros LJ, Prieto VG, Pemmaraju N, Khoury JD. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31109153.
- Singh R, Peng S, Viswanath P, Sambandam V, Shen L, Rao X, Fang B, Wang J, Johnson FM. Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis. EMBO Mol Med 11(5), 2019. e-Pub 2019. PMID: 31040125.
- Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov, 2019. e-Pub 2019. PMID: 30777870.
- Wei SC, Sharma R, Anang NAS, Levine JH, Zhao Y, Mancuso JJ, Setty M, Sharma P, Wang J, Pe'er D, Allison JP. Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity, 2019. e-Pub 2019. PMID: 30926234.
- Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodríguez-Perales S, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkær K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res 7(4):644-657, 2019. e-Pub 2019. PMID: 30745366.
- Peng DH, Kundu ST, Fradette JJ, Diao L, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Mino B, Yang Y, Minelli R, Peoples MD, Bristow CA, Heffernan TP, Carugo A, Wistuba II, Gibbons DL. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Sci Transl Med 11(483), 2019. e-Pub 2019. PMID: 30867319.
- Li CJ, Jiang C, Liu Y, Bell T, Ma W, Ye Y, Huang S, Guo H, Zhang H, Wang L, Wang J, Nomie K, Zhang L, Wang M. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Mol Cancer Ther, 2019. e-Pub 2019. PMID: 30413649.
- Pietanza MC, Diao L, Wang J, Byers LA. Reply to F. Liang. J Clin Oncol:JCO1801153, 2019. e-Pub 2019. PMID: 30496013.
- Gleber-Netto FO, Rao X, Guo T, Xi Y, Gao M, Shen L, Erikson K, Kalu NN, Ren S, Xu G, Fisch KM, Akagi K, Seiwert T, Gillison M, Frederick MJ, Johnson FM, Wang J, Myers JN, Califano J, Skinner HD, Pickering CR. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight 4(1), 2019. e-Pub 2019. PMID: 30626753.
- Yan X, Zhang X, Wang L, Zhang R, Pu X, Wu S, Li L, Tong P, Wang J, Meng Q, Jensen VB, Girard L, Minna JD, Roth JA, Swisher SG, Heymach JV, Fang B. Inhibition of thioredoxin/thioredoxin reductase induces synthetic lethality in lung cancers with compromised glutathione homeostasis. Cancer Res, 2019. e-Pub 2019. PMID: 30401714.
- Choi H, Kwon J, Cho MS, Sun Y, Zheng X, Wang J, Bouker KB, Casey JL, Atkins MB, Toretsky J, Han C. Targeting DDX3X triggers anti-tumor immunity via a dsRNA-mediated tumor-intrinsic type I interferon response. Cancer Res, 2019. e-Pub 2019. PMID: 33941613.
- Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU, Haymaker C, Bernatchez C, Curran M, Zecchini Barrese T, Rodriguez Canales J, Wistuba I, Li L, Wang J, van der Burg SH, Melief CJ, Glisson B. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol, 2019. e-Pub 2019. PMID: 30267032.
- Gay CM, Tong P, Cardnell RJ, Sen T, Su X, Ma J, Bara RO, Johnson FM, Wakefield C, Heymach JV, Wang J, Byers LA. Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. Clin Cancer Res, 2019. e-Pub 2019. PMID: 30257981.
- Tailor TD, Rao X, Campa MJ, Wang J, Gregory SG, Patz EF. Whole Exome Sequencing of Cell-Free DNA for Early Lung Cancer: A Pilot Study to Differentiate Benign From Malignant CT-Detected Pulmonary Lesions. Front Oncol 9:317, 2019. e-Pub 2019. PMID: 31069172.
- Caetano MS, Hassane M, Van HT, Bugarin E, Cumpian AM, McDowell CL, Cavazos CG, Zhang H, Deng S, Diao L, Wang J, Evans SE, Behrens C, Wistuba II, Fuqua SAW, Lin H, Stabile LP, Watowich SS, Kadara H, Moghaddam SJ. Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nat Commun 9(1):4589, 2018. e-Pub 2018. PMID: 30389925.
- Kiyama T, Chen CK, Wang SW, Pan P, Ju Z, Wang J, Takada S, Klein WH, Mao CA. Essential roles of mitochondrial biogenesis regulator Nrf1 in retinal development and homeostasis. Mol Neurodegener 13(1):56, 2018. e-Pub 2018. PMID: 30333037.
- Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG. Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget 9(74):33995-34008, 2018. e-Pub 2018. PMID: 30338041.
- Kalu NN, Mazumdar T, Peng S, Tong P, Shen L, Wang J, Banerjee U, Myers JN, Pickering CR, Brunell D, Stephan CC, Johnson FM. Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. Cancer Lett 431:64-72, 2018. e-Pub 2018. PMID: 29807113.
- Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 8(9):1156-1175, 2018. e-Pub 2018. PMID: 30012853.
- Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36(23):JCO2018777672, 2018. e-Pub 2018. PMID: 29906251.
- Ferrarotto R, Cardnell R, Su S, Diao L, Eterovic AK, Prieto V, Morrisson WH, Wang J, Kies MS, Glisson BS, Byers LA, Bell D. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. Head Neck 40(8):1676-1684, 2018. e-Pub 2018. PMID: 29570891.
- Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li CW, Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, Cristofanilli M, Huo L. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol 77:121-129, 2018. e-Pub 2018. PMID: 29689244.
- Lissanu Deribe Y, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J, Gao G, Mullinax RA, Khor T, Feng N, Lin YH, Wu CC, Reyes C, Peng Q, Robinson F, Inoue A, Kochat V, Liu CG, Asara JM, Moran C, Muller F, Wang J, Fang B, Papadimitrakopoulou V, Wistuba II, Rai K, Marszalek J, Futreal PA. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med 24(7):1047-1057, 2018. e-Pub 2018. PMID: 29892061.
- Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8(7):822-835, 2018. e-Pub 2018. PMID: 29773717.
- Zhang L, Lin J, Ye Y, Oba T, Gentile E, Lian J, Wang J, Zhao Y, Gu J, Wistuba II, Roth JA, Ji L, Wu X. Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clin Pharmacol Ther, 2018. e-Pub 2018. PMID: 28891208.
- Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol 31(6):947-955, 2018. e-Pub 2018. PMID: 29410488.
- Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab 27(5):977-987.e4, 2018. e-Pub 2018. PMID: 29628419.
- Chen H, Li C, Peng X, Zhou Z, Weinstein JN, Research Network CGA, Liang H. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell 173(2):386-399.e12, 2018. e-Pub 2018. PMID: 29625054.
- Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kaminska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwinska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ, Research Network CGA, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173(2):338-354.e15, 2018. e-Pub 2018. PMID: 29625051.
- Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H, Research Network CGA, Piwnica-Worms H, Ma L, Liang H. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Rep 23(1):213-226.e3, 2018. e-Pub 2018. PMID: 29617661.
- Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, Research Network CGA, Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep 23(1):313-326.e5, 2018. e-Pub 2018. PMID: 29617669.
- Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Research Network CGA, Sood AK, Gunaratne PH, Sumazin P. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Rep 23(1):297-312.e12, 2018. e-Pub 2018. PMID: 29617668.
- Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-González H, Chai S, Wang F, Varghese R, Huang M, Liang WW, Wyczalkowski MA, Sengupta S, Li Z, Payne SH, Fenyö D, Miner JH, Walter MJ, Research Network CGA, Vincent B, Eyras E, Chen K, Shmulevich I, Chen F, Ding L. Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Rep 23(1):270-281.e3, 2018. e-Pub 2018. PMID: 29617666.
- Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J, Research Network CGA, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Rep 23(1):181-193.e7, 2018. e-Pub 2018. PMID: 29617659.
- Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Marchand C, Weinstein JN, Research Network CGA, Bathe OF, Liang H. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Rep 23(1):255-269.e4, 2018. e-Pub 2018. PMID: 29617665.
- Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I, Research Network CGA, Monnat RJ, Xiao Y, Wang C. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep 23(1):239-254.e6, 2018. e-Pub 2018. PMID: 29617664.
- Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK, Research Network CGA, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep 23(1):194-212.e6, 2018. e-Pub 2018. PMID: 29617660.
- Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128(4):1267-1282, 2018. e-Pub 2018. PMID: 29324442.
- Wang Y, Tian X, Zhang W, Zhang Z, Lazcano R, Hingorani P, Roth ME, Gill JD, Harrison DJ, Xu Z, Jusu S, Kannan S, Wang J, Lazar AJ, Earley EJ, Erickson SW, Gelb T, Huxley P, Lahdenranta J, Mudd G, Kurmasheva RT, Houghton PJ, Smith MA, Kolb EA, Gorlick R. Comprehensive surfaceome profiling to identify and validate novel cell-surface targets in osteosarcoma. Mol Cancer Ther, 2018. e-Pub 2018. PMID: 35312779.
- Sandulache VC, Michikawa C, Kataria P, Gleber-Netto FO, Bell D, Trivedi S, Rao X, Wang J, Zhao M, Jasser SA, Myers JN, Pickering CR. High-risk TP53 mutations are associated with extra nodal extension (ENE) in oral cavity squamous cell carcinoma (OSCC). Clin Cancer Res, 2018. e-Pub 2018. PMID: 29330202.
- Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, Sofia HJ, Hutter C, Getz G, Wheeler D, Ding L, Group MC, Research Network CGA. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst 6(3):271-281.e7, 2018. e-Pub 2018. PMID: 29596782.
- Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C, Atlas Network CG. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Syst 6(3):282-300.e2, 2018. e-Pub 2018. PMID: 29596783.
- Zhang H, Li HS, Hillmer EJ, Zhao Y, Chrisikos TT, Hu H, Wu X, Thompson EJ, Clise-Dwyer K, Millerchip KA, Wei Y, Puebla-Osorio N, Kaushik S, Santos MA, Wang B, Garcia-Manero G, Wang J, Sun SC, Watowich SS. Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 antiinflammatory activity in hematopoiesis. Proc Natl Acad Sci U S A 115(10):E2311-E2319, 2018. e-Pub 2018. PMID: 29463696.
- Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV. Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget 9(18):14268-14284, 2018. e-Pub 2018. PMID: 29581842.
- Wang JF, Pu X, Zhang X, Chen K, Xi Y, Wang J, Mao X, Zhang J, Heymach JV, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Meng QH, Shaw KR, Eterovic AK, Fang B. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer, 2018. e-Pub 2018. PMID: 29178133.
- Tanaka N, Zhao M, Tang L, Patel AA, Xi Q, Van HT, Takahashi H, Osman AA, Zhang J, Wang J, Myers JN, Zhou G. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1. Oncogene, 2018. e-Pub 2018. PMID: 29269868.
- Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, Atlas Network CG, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell 33(2):244-258.e10, 2018. e-Pub 2018. PMID: 29438696.
- Carey JP, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer. Cancer Res, 2018. e-Pub 2018. PMID: 29180466.
- Gadhikar MA, Zhang J, Shen L, Rao X, Wang J, Zhao M, Kalu NN, Johnson FM, Byers LA, Heymach J, Hittelman WN, Udayakumar D, Pandita RK, Pandita TK, Pickering CR, Redwood A, Piwnica-Worms H, Schlacher K, Frederick MJ, Myers JN. CDKN2A/p16 deletion in head and neck cancer cells is associated with Cdk2 activation, replication stress, and vulnerability to Chk1 inhibition. Cancer Res, 2018. e-Pub 2018. PMID: 29229598.
- Meraz IM, Majidi M, Cao X, Lin H, Li L, Wang J, Baladandayuthapani V, Rice D, Sepesi B, Ji L, Roth JA. TUSC2 immunogene synergizes with anti-PD1 through enhanced proliferation and infiltration of natural killer cells in syngeneic Kras-mutant mouse lung cancer models. Cancer Immunol Res, 2018. e-Pub 2018. PMID: 29339375.
- Wang Y, Gudikote J, Giri U, Yan J, Deng W, Ye R, Jiang W, Li N, Hobbs BP, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach JV, Lin SH. RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer. Clin Cancer Res, 2018. e-Pub 2018. PMID: 29030353.
- Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR, Head, Supplement Consortium NCSPOREHIV. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124(1):84-94, 2018. e-Pub 2018. PMID: 29053175.
- Deshpande A, Lang W, McDowell T, Sivakumar S, Zhang J, Wang J, San Lucas FA, Fowler J, Kadara H, Scheet P. Strategies for identification of somatic variants using the Ion Torrent deep targeted sequencing platform. BMC Bioinformatics 19(1):5, 2018. e-Pub 2018. PMID: 29301485.
- Cao X, Zhao Y, Wang J, Dai B, Gentile E, Lin J, Pu X, Ji L, Wu S, Meraz I, Majidi M, Roth JA. TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC). Oncotarget 8(64):107621-107629, 2017. e-Pub 2017. PMID: 29296193.
- Morris VK, Rao X, Pickering CR, Foo WC, Rashid A, Eterovic AK, Kim TB, Chen K, Wang J, Shaw K, Eng C. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Mol Cancer Res, 2017. e-Pub 2017. PMID: 28784613.
- Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Sci Transl Med 9(415), 2017. e-Pub 2017. PMID: 29118262.
- address: elizabethdemicco@sinaihealthsystemca CGARNE, Research Network CGA. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171(4):950-965.e28, 2017. e-Pub 2017. PMID: 29100075.
- Tanaka N, Patel AA, Tang L, Silver NL, Lindemann A, Takahashi H, Jaksik R, Rao X, Kalu NN, Chen TC, Wang J, Frederick MJ, Johnson F, Gleber-Netto FO, Fu S, Kimmel M, Wang J, Hittelman WN, Pickering CR, Myers JN, Osman AA. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation. Clin Cancer Res 23(21):6541-6554, 2017. e-Pub 2017. PMID: 28790110.
- Kalu NN, Mazumdar T, Peng S, Shen L, Sambandam V, Rao X, Xi Y, Li L, Qi Y, Gleber-Netto FO, Patel A, Wang J, Frederick MJ, Myers JN, Pickering CR, Johnson FM. Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget 8(49):86369-86383, 2017. e-Pub 2017. PMID: 29156801.
- Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG. JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer. Mol Cancer Ther, 2017. e-Pub 2017. PMID: 28729401.
- Sen T, Tong P, Diao L, Li L, Fan Y, Hoff J, Heymach J, Wang J, Byers LA. Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small cell lung cancer. Clin Cancer Res, 2017. e-Pub 2017. PMID: 28698200.
- Jonasch E, Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Cancer Res 77(19):5313-5326, 2017. e-Pub 2017. PMID: 28807937.
- Cardnell RJ, Li L, Sen T, Bara R, Tong P, Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, Kalu NN, Fan YH, Dylla SJ, Johnson FM, Wistuba II, Oliver TG, Heymach JV, Glisson BS, Wang J, Byers LA. Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget 8(43):73419-73432, 2017. e-Pub 2017. PMID: 29088717.
- Jung KH, Yoo W, Stevenson HL, Deshpande D, Shen H, Gagea M, Yoo SY, Wang J, Eckols TK, Bharadwaj U, Tweardy DJ, Beretta L. Multi-functional effects of a small-molecule STAT3 inhibitor on NASH and HCC in mice. Clin Cancer Res, 2017. e-Pub 2017. PMID: 28533225.
- Xie VK, Li Z, Yan Y, Jia Z, Zuo X, Zhenjin J, Wang J, Du J, Xie D, Wei D, Xie K. DNA-methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Krüppel-like factor 4 Expression. Clin Cancer Res, 2017. e-Pub 2017. PMID: 28659310.
- Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells KJ, Haddad V, Hanrahan EO, Nilsson M, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Juergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach J. The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer. Clin Cancer Res, 2017. e-Pub 2017. PMID: 28559461.
- Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170(6):1120-1133.e17, 2017. e-Pub 2017. PMID: 28803728.
- Chen TW, Lee CC, Liu H, Wu CS, Pickering CR, Huang PJ, Wang J, Chang IY, Yeh YM, Chen CD, Li HP, Luo JD, Tan BC, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang WF, Rodriguez H, Myers JN, Chang KP, Chang YS. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. Nat Commun 8(1):465, 2017. e-Pub 2017. PMID: 28878238.
- Lin J, Zandi R, Shao R, Gu J, Ye Y, Wang J, Zhao Y, Pertsemlidis A, Wistuba II, Wu X, Roth JA, Ji L. A miR-SNP biomarker linked to an increased lung cancer survival by miRNA-mediated down-regulation of FZD4 expression and Wnt signaling. Sci Rep 7(1):9029, 2017. e-Pub 2017. PMID: 28831115.
- Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Dybkær K, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Wang S, Møller MB, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH. Role of AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol, 2017. e-Pub 2017. PMID: 28627414.
- Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res 77(14):3870-3884, 2017. e-Pub 2017. PMID: 28490518.
- Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun 8:15916, 2017. e-Pub 2017. PMID: 28653662.
- Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, Pickering CR, Byers LA, Williams MD, Wang J, Shen L, Yoo SY, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clin Cancer Res 23(11):2713-2722, 2017. e-Pub 2017. PMID: 28476872.
- Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ, Myung JH, Heymach JV, Johnson FM, Hong S, Zheng L, Hu S, Villalobos PA, Behrens C, Wistuba I, Freemantle S, Liu X, Dmitrovsky E. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. J Natl Cancer Inst 109(6), 2017. e-Pub 2017. PMID: 28376145.
- Xie X, Kaoud TS, Edupuganti R, Zhang T, Kogawa T, Zhao Y, Chauhan GB, Giannoukos DN, Qi Y, Tripathy D, Wang J, Gray NS, Dalby KN, Bartholomeusz C, Ueno NT. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. Oncogene 36(18):2599-2608, 2017. e-Pub 2017. PMID: 27941886.
- Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu NN, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett 392:71-82, 2017. e-Pub 2017. PMID: 28126323.
- Peng DH, Ungewiss C, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Uraoka N, Mino B, Behrens C, Wistuba II, Han RI, Wanna CA, Fahrenholtz M, Grande-Allen KJ, Creighton CJ, Gibbons DL. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene 36(14):1925-1938, 2017. e-Pub 2017. PMID: 27694892.
- Stewart CA, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget 8(17):28575-28587, 2017. e-Pub 2017. PMID: 28212573.
- Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, Wang J, Lu Y, Byers LA, Perou CM, Lin SY, Mills GB. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Sci Adv 3(4):e1600957, 2017. e-Pub 2017. PMID: 28439535.
- Research Network CGA, of Medicine AEC, Services AB, Hospital BC, of Medicine BC, of Hope BRIOC, on Aging BIFR, Sciences Centre CMSG, School HM, Cancer Center HFG, Health Services RIACC, for Biotechnology HI, ILSbio, LLC, of Medicine IUS, Human Virology IO, Systems Biology IF, Consortium IG, Biomedical L, Hospital MG, Washington University MGIA, of Wisconsin MC, South Carolina MUO, Cancer Center MSK, Center MM, NantOmics, Institute NC, Hospital N, Abuja, Nigeria, Research Institute NHG, Health Sciences NIOE, on Deafness NI, Disorders OC, Bank OT, Sciences Centre LH, Bank OT, Cancer Research OIF, Bank OT, Hospital TO, Health O, University S, Cancer Institute SOC, Center CM, International SRA, Health System SJC, Eli, of Technology ELBIOMI, University H, Children's Hospital RIAN, Hopkins University SKCCCAJ, Bergen UO, Cancer Center UOTMA, Teaching Hospital UOA, at Birmingham UOA, California UO, Irvine, Santa Cruz UOC, Medical Center UOK, Lausanne UO, Sciences Center UONMH, Chapel Hill UONCA, Health Scien UOO. Integrated genomic and molecular characterization of cervical cancer. Nature 543(7645):378-384, 2017. e-Pub 2017. PMID: 28112728.
- Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol 35(3):352-360, 2017. e-Pub 2017. PMID: 27870570.
- Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Hung MC, Sood AK, Shureiqi I. Metastasis regulation by PPARD expression in cancer cells. JCI Insight 2(1):e91419, 2017. e-Pub 2017. PMID: 28097239.
- Yoo W, Gjuka D, Stevenson HL, Song X, Shen H, Yoo SY, Wang J, Fallon M, Ioannou GN, Harrison SA, Beretta L. Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. PLoS One 12(12):e0189965, 2017. e-Pub 2017. PMID: 29244873.
- Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH. Assessment of CD37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood 128(26):3083-3100, 2016. e-Pub 2016. PMID: 27760757.
- Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, Wang J, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Pham LV, Young KH. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging (Albany NY) 8(12):3321-3340, 2016. e-Pub 2016. PMID: 27941215.
- Wang Y, Liu H, Diao L, Potter A, Zhang J, Qiao Y, Wang J, Proia DA, Tailor R, Komaki R, Lin SH. Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. Clin Cancer Res, 2016. e-Pub 2016. PMID: 27354472.
- Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. IGF-1R and mTOR Blockade: Novel Resistance Mechnaisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst 108(12), 2016. e-Pub 2016. PMID: 27576731.
- Xiaobo C, Majidi M, Feng M, Shao R, Wang J, Zhao Y, Baladandayuthapani V, Song J, Fang B, Ji L, Mehran R, Roth JA. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin. Sci Rep 6:35741, 2016. e-Pub 2016. PMID: 27845352.
- Fang P, Rao X, Wang J, Maru D, Lin SH. Differential Expression of Immuno-oncologic Genes in Esophageal Cancer Patients With Complete Pathologic Response to Chemoradiation. Int J Radiat Oncol Biol Phys, 2016. e-Pub 2016. PMID: 2673952.
- Skinner HD, Giri U, Yang L, Woo SH, Story MD, Pickering CR, Byers LA, Williams MD, El-Naggar A, Wang J, Diao L, Shen L, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Proteomic profiling identifies PTK2/FAK as a driver of radioresistance in HPV negative head and neck cancer. Clin Cancer Res, 2016. e-Pub 2016. PMID: 27036135.
- Chen L, Yi X, Goswami S, Ahn YH, Roybal JD Yang Y, Diao L, Peng D, Pend D, Fradette JJ, Wang J, Byers LA, Kurie JM, Ullrich SE, Qin FF, Gibbons DL. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncolmmunology, 2016. e-Pub 2016. PMID: 27999749.
- Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, Bui TN, Warner S, Heymach JV, Hunt KK, Wang J, Byers LA, Keyomarsi K. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Mol Cancer Res, 2016. e-Pub 2016. PMID: 27671334.
- Treekitkarnmongkol W, Katayama H, Kai K, Sasai K, Jones JC, Wang J, Shen L, Sahin AA, Gagea Iurascu M, Ueno NT, Creighton CJ, Sen S. Aurora Kinase-A Overexpression in Mouse Mammary Epithelium Induces Mammary Adenocarcinomas Harboring Genetic Alterations Shared with Human Breast Cancer. Carcingogeneis, 2016. e-Pub 2016. PMID: 27624071.
- Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, Rodriguez JC, Hwu P, Wistuba II, Heymach JV, Gibbons DL. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res 22(14):3630-42, 2016. e-Pub 2016. PMID: 26851185.
- Jakubek Y, Lang W, Vattathil S, Garcia M, Xu L, Huang L, Yoo SY, Shen L, Lu W, Chow CW, Weber Z, Davies G, Huang J, Behrens C, Kalhor N, Moran C, Fujimoto J, Mehran R, El-Zein R, Swisher SG, Wang J, Fowler J, Spira AE, Ehli EA, Wistuba II, Scheet P, Kadara H. Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway. Cancer Res 76(13):3676-83, 2016. e-Pub 2016. PMID: 27216194.
- Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget, 2016. e-Pub 2016. PMID: 27384992.
- Rojas A, Zhang P, Wang Y, Foo WC, Muñoz NM, Xiao L, Wang J, Gores GJ, Hung MC, Blechacz B. A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. Neoplasia 18(6):371-86, 2016. e-Pub 2016. PMID: 27292026.
- Lin FM, Kumar S, Ren J, Karami S, Bahnassy S, Li Y, Zheng X, Wang J, Bawa-Khalfe T. SUMOylation of HP1α supports association with ncRNA to define responsiveness of breast cancer cells to chemotherapy. Oncotarget, 2016. e-Pub 2016. PMID: 27107417.
- Sambandam V, Frederick MJ, Shen L, Tong P, Rao X, Peng S, Singh R, Mazumdar T, Huang C, Li Q, Pickering CR, Myers JN, Wang J, Johnson FM. PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition. Clin Cancer Res, 2016. e-Pub 2016. PMID: 30770351.
- Nilsson M, Giri U, Gudikote J, Tang X, Lu W, Tran HT, Fan YH, Koo A, Diao L, Tong P, Wang J, Herbst RS, Johnson BE, Ryan AJ, Webster A, Rowe P, Wistuba II, Heymach JV. KDR AMPLIFICATION IS ASSOCIATED WITH VEGF-INDUCED ACTIVATION OF mTOR AND INVASION PATHWAYS BUT DOES NOT PREDICT CLINICAL BENEFIT TO THE VEGFR TKI VANDETANIB. Clin Cancer Res, 2016. e-Pub 2016. PMID: 26578684.
- Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna JD, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res, 2016. e-Pub 2016. PMID: 26597303.
- Liu X, Xiao ZD, Han L, Zhang J, Lee SW, Wang W, Lee H, Zhuang L, Chen J, Lin HK, Wang J, Liang H, Gan B. LncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress. Nat Cell Biol 18(4):431-42, 2016. e-Pub 2016. PMID: 26999735.
- Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, Liu CG, Liu X, Lin F, Symmans WF, Wei W, Zhang X, Sun L, Alvarez RH, Ueno NT, Fouad TM, Harano K, Debeb BG, Wu Y, Reuben J, Cristofanilli M, Zuo Z. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol 29(4):330-46, 2016. e-Pub 2016. PMID: 26916073.
- Ho TH, Park IY, Zhao H, Tong P, Champion MD, Yan H, Monzon FA, Hoang A, Tamboli P, Parker AS, Joseph RW, Qiao W, Dykema K, Tannir NM, Castle EP, Nunez-Nateras R, Teh BT, Wang J, Walker CL, Hung MC, Jonasch E. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene, 2016. e-Pub 2016. PMID: 26073078.
- Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra-Cuentas ER, Wistuba II, Soucheray M, Thai T, Asahina H, Kitajima S, Altabef A, Cavanaugh JD, Rhee K, Gao P, Zhang H, Fecci PE, Shimamura T, Hellmann MD, Heymach JV, Hodi FS, Freeman GJ, Barbie DA, Dranoff G, Hammerman PS, Wong KK. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res 76(5):999-1008, 2016. e-Pub 2016. PMID: 26833127.
- Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res, 2016. e-Pub 2016. PMID: 26420858.
- Kundu ST, Byers LA, Peng DH, Roybal JD, Diao L, Wang J, Tong P, Creighton CJ, Gibbons DL. The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. Oncogene, 2016. e-Pub 2016. PMID: 25798833.
- Peng S, Sen B, Mazumdar T, Byers LA, Diao L, Wang J, Tong P, Giri U, Heymach JV, Kadara HN, Johnson FM. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. Oncotarget 7(1):565-79, 2016. e-Pub 2016. PMID: 26623721.
- Tong P, Diao L, Shen L, Li L, Heymach JV, Girard L, Minna JD, Coombes KR, Byers LA, Wang J. Selecting Reliable mRNA Expression Measurements Across Platforms Improves Downstream Analysis. Cancer Inform 15:81-9, 2016. e-Pub 2016. PMID: 27199546.
- Cardnell RJ, Feng Y, Mukherjee S, Diao L, Tong P, Stewart CA, Masrorpour F, Fan Y, Nilsson M, Shen Y, Heymach JV, Wang J, Byers LA. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. PLoS One 11(4):e0152584, 2016. e-Pub 2016. PMID: 27055253.
- Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman SM, Mao L, Saintigny P. New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development. Cancer Prev Res (Phila) 8(11):1027-35, 2015. e-Pub 2015. PMID: 26342026.
- Ye X, Fan F, Bhattacharya R, Bellister S, Boulbes DR, Wang R, Xia L, Ivan C, Zheng X, Calin GA, Wang J, Lu X, Ellis LM. VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells. Mol Cancer Res 13(9):1274-82, 2015. e-Pub 2015. PMID: 26041938.
- Cardnell RJ, Behrens C, Diao L, Fan Y, Tang X, Tong P, Minna JD, Mills GB, Heymach JV, Wistuba II, Wang J, Byers LA. An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clin Cancer Res 21(15):3480-91, 2015. e-Pub 2015. PMID: 25878335.
- Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5(8):860-77, 2015. e-Pub 2015. PMID: 26069186.
- Tong P, Coombes KR, Johnson FM, Byers LA, Diao L, Liu DD, Lee JJ, Heymach JV, Wang J. drexplorer: A tool to explore dose-response relationships and drug-drug interactions. Bioinformatics 31(10):1692-4, 2015. e-Pub 2015. PMID: 25600946.
- Atlas Network CG. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517(7536):576-82, 2015. e-Pub 2015. PMID: 25631445.
- Dai B, Yan S, Lara-Guerra H, Kawashima H, Sakai R, Jayachandran G, Majidi M, Mehran R, Wang J, Bekele BN, Baladandayuthapani V, Yoo SY, Wang Y, Ying J, Meng F, Ji L, Roth JA. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy. PLoS One 10(6):e0123967, 2015. e-Pub 2015. PMID: 26053020.
- Research Network CGA. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543-50, 2014. e-Pub 2014. PMID: 25079552.
- Riquelme E, Suraokar M, Behrens C, Lin HY, Girard L, Nilsson MB, Simon G, Wang J, Coombes KR, Lee JJ, Hong WK, Heymach J, Minna JD, Wistuba II. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res 20(14):3849-61, 2014. e-Pub 2014. PMID: 24850841.
- Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C, Rice D, Mehran R, Lee JJ, Pass HI, Wang J, Momin AA, James BP, Corvalan A, Coombes K, Tsao A, Wistuba II. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol 25(6):1184-92, 2014. e-Pub 2014. PMID: 24669013.
- Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. An integrin β -KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol 16(5):457-68, 2014. e-Pub 2014. PMID: 24747441.
- Kadara H, Fujimoto J, Yoo SY, Maki Y, Gower AC, Kabbout M, Garcia MM, Chow CW, Chu Z, Mendoza G, Shen L, Kalhor N, Hong WK, Moran C, Wang J, Spira A, Coombes KR, Wistuba II. Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. J Natl Cancer Inst 106(3):dju004, 2014. e-Pub 2014. PMID: 24563515.
- Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Jones S, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241, 2014. e-Pub 2014. PMID: 25348003.
- Lin SH, Wang J, Saintigny P, Wu CC, Giri U, Zhang J, Menju T, Diao L, Byers L, Weinstein JN, Coombes KR, Girard L, Komaki R, Wistuba II, Date H, Minna JD, Heymach JV. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics 15:1079, 2014. e-Pub 2014. PMID: 25486910.
- Wang J, Raimondo M, Guha S, Chen J, Diao L, Dong X, Wallace MB, Killary AM, Frazier ML, Woodward TA, Wang J, Sen S. Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. J Cancer 5(8):696-705, 2014. e-Pub 2014. PMID: 25258651.
- Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, Byers LA. Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer. Clin Cancer Res 19(22):6322-8, 2013. e-Pub 2013. PMID: 24077350.
- Blumenshein GR JR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst R, Alden CM, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella F, Tran HT, Mao L, Hicks ME, Erasms K, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba II, Hong WK, Heymach JV, Lippman SM. Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) Trial. Clin Cancer Res, 2013. e-Pub 2013. PMID: 24166906.
- Pickering CR, Shah K, Ahmed S, Rao A, Frederick MJ, Zhang J, Unruh AK, Wang J, Ginsberg LE, Kumar AJ, Myers JN, Hamilton JD. CT imaging correlates of genomic expression for oral cavity squamous cell carcinoma. AJNR Am J Neuroradiol 34(9):1818-22, 2013. e-Pub 2013. PMID: 23764725.
- Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K, Drummond J, Cortez E, Xie TX, Zhang D, Chung W, Issa JP, Zweidler-McKay PA, Wu X, El-Naggar AK, Weinstein JN, Wang J, Muzny DM, Gibbs RA, Wheeler DA, Myers JN, Frederick MJ. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov, 2013. e-Pub 2013. PMID: 23619168.
- Kim YW, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J, Wang J, Almeida JS, Aldape K, Yung WK. Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro Oncol, 2013. e-Pub 2013. PMID: 23502430.
- Chauhan S, Goodwin JG, Chauhan S, Manyam G, Wang J, Kamat AM, Boyd DD. ZKSCAN3 is a master transcriptional repressor of autophagy. Mol Cell 50(1):16-28, 2013. e-Pub 2013. PMID: 23434374.
- Mao CA, Cho JH, Wang J, Gao Z, Pan P, Tsai WW, Frishman LJ, Klein WH. Reprogramming amacrine and photoreceptor progenitors into retinal ganglion cells by replacing Neurod1 with Atoh7. Development 140(3):541-51, 2013. e-Pub 2013. PMID: 23293286.
- Yan W, Shih J, Rodriguez-Canales J, Tangrea MA, Player A, Diao L, Hu N, Goldstein AM, Wang J, Taylor PR, Lippman SM, Wistuba II, Emmert-Buck MR, Erickson HS. Three-Dimensional mRNA Measurements Reveal Minimal Regional Heterogeneity in Esophageal Squamous Cell Carcinoma. Am J Pathol 182(2):529-39, 2013. e-Pub 2013. PMID: 23219752.
- Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19(1):279-90, 2013. e-Pub 2013. PMID: 23091115.
- Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, Chu Z, Garcia M, Kabbout M, Fan YH, Behrens C, Liu DA, Mao L, Lee JJ, Gold KA, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II. Characterizing the molecular spatial and temporal field of injury in early stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila) 6(1):8-17, 2013. e-Pub 2013. PMID: 23087048.
- Menge T, Zhao Y, Zhao J, Wataha K, Gerber M, Zhang J, Letourneau P, Redell J, Shen L, Wang J, Peng Z, Xue H, Kozar R, Cox CS, Khakoo AY, Holcomb JB, Dash PK, Pati S. Mesenchymal Stem Cells Regulate Blood-Brain Barrier Integrity Through TIMP3 Release After Traumatic Brain Injury. Sci Transl Med 4(161):161ra150, 2012. e-Pub 2012. PMID: 23175708.
- Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2(9):798-811, 2012. e-Pub 2012. PMID: 22961666.
- Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 104(3):228-39, 2012. e-Pub 2012. PMID: 22247021.
- Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM. Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 18(3):726-36, 2012. e-Pub 2012. PMID: 22298898.
- Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer 48(1):12-23, 2012. e-Pub 2012. PMID: 21741824.
- Lamothe B, Lai Y, Hur L, Orozco NM, Wang J, Campos AD, Xie M, Schneider MD, Lockworth CR, Jakacky J, Tran D, Ho M, Dawud S, Dong C, Lin HK, Hu P, Estrov Z, Bueso-Ramos CE, Darnay BG. Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice. PLoS One 7(12):e51228, 2012. e-Pub 2012. PMID: 23251462.
- He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Guo C, Wang L, Guo W, Pataer A, Correa AM, Lu Y, Wang J, Diao L, Byers LA, Wistuba II, Roth JA, Swisher SG, Heymach JV, Fang B. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One 7(2):e31087, 2012. e-Pub 2012. PMID: 22348039.
- Zhou W, Bolden-Tiller OU, Shao SH, Weng CC, Shetty G, Abuelhija M, Pakarinen P, Huhtaniemi I, Momin AA, Wang J, Stivers DN, Liu Z, Meistrich ML. Estrogen-Regulated Genes in Rat Testes and Their Relationship to Recovery of Spermatogenesis after Irradiation. Biol Reprod, 2011. e-Pub 2011. PMID: 21653891.
- Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 Gene Copy Is Associated With Chemoresistance and Shorter Survival in Patients with Non-small Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. Cancer Res, 2011. e-Pub 2011. PMID: 21724587.
- Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN. Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1. Science 333(6046):1154-7, 2011. e-Pub 2011. PMID: 21798897.
- Kim YW, Liu TJ, Koul D, Tiao N, Feroze AH, Wang J, Powis G, Yung WK. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. Neuro Oncol 13(4):367-75, 2011. e-Pub 2011. PMID: 21430111.
- Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering C, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Perticoin III, EF, Calvert V, Fondale V, Wang J, Weber RS. Phosphoproteomic Analysis of Signaling Pathways in Head and Neck Squamous Cell Carcinoma Patient Samples. American Journal of Pathology 178(2):548-71, 2011. e-Pub 2011.
- Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Fraser Symmans W, Hortobagyi GN, Andre F, Pusztai L. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat, 2010. e-Pub 2010. PMID: 20024612.
- Nanjundan M, Byers LA, Carey M, Siwak D, Wistuba I, Diao L, Wang J, Coombes KR, Mills GB, Minna J, Heymach JV. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thor Onc(10):1097, 2010. e-Pub 2010.
- Hudson LG, Gale JM, Padilla RS, Pickett G, Alexander BE, Wang J, Kusewitt DF. Microarray analysis of cutaneous squamous cell carcinomas reveals enhanced expression of epidermal differentiation complex genes. Mol Carcinog 49(7):619-29, 2010. e-Pub 2010. PMID: 20564339.
- Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, Kiesel L, Hess K, Baggerly KA, Coombes KR, Pusztai L. Clinical Evaluation of Chemotherapy Response Predictors Developed from Breast Cancer Cell Lines. Breast Cancer Res Treat 121(2):301-9, 2010. e-Pub 2010. PMID: 19603265.
- Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D, Myers JN. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 29(14):2047-59, 2010. e-Pub 2010. PMID: 20101235.
- Wang J, Byers LA, Yordy JS, Liu W, Shen L, Baggerly KA, Giri U, Myers JN, Ang KK, Story MD, Girad L, Minna JD, Heymach JV, Coombes KR. Blasted Cell Line Names. Cancer Informatics(9):251-255, 2010. e-Pub 2010.
- Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer. Clin Cancer Res 15(22):6852-61, 2009. e-Pub 2009. PMID: 19861436.
- Wang J, Wen S, Symmans WF, Pusztai L, Coombes KR. The Bimodality Index: A Criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data. Cancer Inform 7:199-216, 2009. e-Pub 2009. PMID: 19718451.
- Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-710, 2008. e-Pub 2008. PMID: 18618013.
- Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans WF, Pusztai L. Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res 10(2):R37, 2008. e-Pub 2008. PMID: 18445275.
- Coombes KR, Wang J, Baggerly KA. Microarrays:retracing steps. Nat Med 13(11):1276-7;author reply, 2007. e-Pub 2007.
- Kupferman ME, Patel V, Sriuranpong V, Amornphimoltham P, Jasser SA, Mandal M, Zhou G, Wang J, Coombes K, Multani A, Pathak S, Silvio Gutkind J, Myers JN. Molecular Analysis of Anoikis Resistance in Oral Cavity Squamous Cell Carcinoma. Oral Oncol 43(5):440-54, 2007. e-Pub 2007. PMID: 16978912.
- Gold DL, Coombes KR, Wang J, Mallick B. Enrichment Analysis in High-throughput Genomics: Accounting for Dependency in the NULL. Briefings in Bioinformatics 8(2):71-7, 2007. e-Pub 2007.
- Wang J, Do KA, Wen S, Tsavachidis S, McDonnell TJ, Logothetis CK, Coombes KR. Merging Microarray Data, Robust Feature Selection, and Predicting Prognosis in Prostate Cancer. Cancer Informatics(2):87-97, 2007. e-Pub 2007. PMID: 1945876.
- Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. CD40 Signaling Predicts Response to Preoperative Trastuzumab and Concomitant Paclitaxel Followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide in HER-2-Overexpressing Breast Cancer. Breast Cancer Res 9(6):R87, 2007. e-Pub 2007. PMID: 18086299.
- Morris J, Wu C, Coombes KR, Baggerly KA, Wang J, Zhang L. Alterative probeset definitions for combining microarray data across studies using different version of Affymetrix oligonucleotide arrays. Meta Analysis in Genetics, 2006. e-Pub 2006.
- Ji Y, Coombes K, Zhang J, Wen S, Mitchell J, Pusztai L, Symmans WF, Wang J. RefSeq refinements of UniGene-based gene matching improve the correlation of expression measurements between two microarray platforms. Appl Bioinformatics 5(2):89-98, 2006. e-Pub 2006. PMID: 16722773.
- Gold DL, Coombes KR, Wang J, Mallick B. Enrichment Analysis in High-throughput Genomics-Accounting for Dependency in the NULL. Briefings in Bioinformatics 8(2):71-77, 2006. e-Pub 2006. PMID: 17077137.
- Abruzzo LV, Wang J, Kapoor M, Medeiros LJ, Keating MJ, Edward Highsmith W, Barron LL, Cromwell CC, Coombes KR. Biological validation of differentially expressed genes in chronic lymphocytic leukemia identified by applying multiple statistical methods to oligonucleotide microarrays. J Mol Diagn 7(3):357-67, 2005. e-Pub 2005. PMID: 16049305.
- Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold DL, Ross JS, Hess KR, Tirrell S, Linette G, Hortobagyi GN, Fraser Symmans W, Pusztai L. Comparsion of the Predictive Accuracy of DNA Array-Based Multigene Classifiers Across cDNA Arrays and Affymetrix GeneChips. J Mol Diagn 7(3):357-367, 2005. e-Pub 2005. PMID: 16049308.
- Ji Y, Wu C, Liu P, Wang J, Coombes KR. Applications of beta-mixture models in bioinformatics. Bioinformatics 21(9):2118-22, 2005. e-Pub 2005. PMID: 15713737.
- Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold D, Ross J, Hess K, Tirrell S, Linette G, Hortobagyi G, Symmans W, Pusztai L. Cross platform comparison of multi-gene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips from the same RNA. J Mol Diagn 7:337-45, 2005. e-Pub 2005. PMID: 16049308.
- Gold DL, Wang J, Coombes KR. Inter-gene correlation on oligonucleotide arrays: how much does normalization matter?. Am J Pharmacogenomics 5(4):271-79, 2005. e-Pub 2005. PMID: 16078863.
- Wang J, Coombes KR, Highsmith WE, Keating MJ, Abruzzo LV. Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. Bioinformatics 20(17):3166-78, 2004. e-Pub 2004. PMID: 15231529.
- Baggerly KA, Morris JS, Wang J, Gold D, Xiao LC, Coombes KR. A comprehensive approach to the analysis of matrix-assisted laser desorption/ionization-time of flight proteomics spectra from serum samples. Proteomics 3(9):1667-72, 2003. e-Pub 2003. PMID: 12973722.
- McCarthy H, Wierda WG, Barron LL, Cromwell CC, Wang J, Coombes KR, Rangel R, Elenitoba-Johnson KS, Keating MJ, Abruzzo LV. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood 101(12):4903-8, 2003. e-Pub 2003. PMID: 12586616.
- Wang J, Hu L, Hamilton SR, Coombes KR, Zhang W. RNA amplification strategies for cDNA microarray experiments. Biotechniques 34(2):394-400, 2003. e-Pub 2003. PMID: 12613262.
- Hu L, Wang J, Baggerly K, Wang H, Fuller GN, Hamilton SR, Coombes KR, Zhang W. Obtaining reliable information from minute amounts of RNA using cDNA microarrays. BMC Genomics 3(1):1-8, 2002. e-Pub 2002. PMID: 12086591.
- Wang J, Jian-Geng Y, Guo B, Klima T, Lal BN, Willerson JT, Casscells WS. Near-Infrared spectroscopic characterization of human advanced atherosclerotic plaques . Journal of American College of Cardiology 39:1305-13, 2002. e-Pub 2002.
- Ramdas L, Wang J, Hu L, Cogdell D, Taylor E, Zhang W. Comparative Evaluation of Laser-based Microarray Scanners. Biotechniques 31(3):546-52, 2001. e-Pub 2001. PMID: 11570499.
- Wang J, Oppenheimer L, Fata P, Pintin J, Stimpson R, Mantsch H. Spectroscopic approach to capillary–alveolar membrane damage induced acute lung injury. Canadian Respiratory Journal 6:499-506, 1999. e-Pub 1999. PMID: 10623786.
- Wang J, Fata P, Yip B, Oppenheimer L, O’Connor R, Stimpson R, Mantsch H. Infrared Spectroscopic Micro-imaging of Macromolecular Leakage in acute Lung Injury Tissue. Microscopy and Microanalysis, Portland, OR, 1999. e-Pub 1999.
- Taga K, Sowa M, Wang J, Etori H, Yoshida T, Okabashi H, Mantsch H. FT-IR spectra of glycine oligomers. Vibrational Spectroscopy 14:143-46, 1997. e-Pub 1997.
- Wang J, Sowa M, Mantsch H, Bittner A, Heise A. Comparison of Different Infrared Measurement Techniques in the Clinical Analysis of Biofluids. Trends in Analytical Chemistry 15:286-96, 1996. e-Pub 1996.
- Sowa M, Wang J, Schultz C, Ahmed M, Mantsch H. Infrared spectroscopic Investigation of In-vivo and Ex-vivo Human Nails. Vibrational Spectroscopy 10:49-56, 1995. e-Pub 1995.
- Chen J, Kobes R, Wang J. Finite-size effects in metallic superlattice systems. Can. J. Phy 73:545-53, 1995. e-Pub 1995.
- Wang J, Sowa M, Ahmed M, Mantsch H. Photoacoustic Near Infrared Investigation of Homo-Polypeptides. Journal of Physical Chemistry 98:4748- 55, 1994. e-Pub 1994.
- Wang J, Ahmed M, Sowa M, Mantsch H. Near Infrared Study of Model Peptides. Intern. Society Optical Eng 2089:492-93, 1993. e-Pub 1993.
Invited Articles
- Cardnell RJ, Byers LA, Wang J. Integrated Approaches for the Use of Large Datasets to Identify Rational Therapies for the Treatment of Lung Cancers. Cancers (Basel) 11(2), 2019. e-Pub 2019. PMID: 30791396.
- Wang J, Byers LA. Teaching an old dog new tricks: drug repositioning in small cell lung cancer. Cancer Discov 3(12):1333-5, 2013. e-Pub 2013. PMID: 24327694.
Review Articles
- Shah PA, Huang C, Li Q, Kazi SA, Byers LA, Wang J, Johnson FM, Frederick MJ. NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. Cells 9(12), 2020. e-Pub 2020. PMID: 33322834.
- Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31137625.
Other Articles
- Sun, H, Cao, S, Mashl, RJ, Mo, CK, Zaccaria, S, Wendl, MC, Davies, S, Bailey, MH, Primeau, T, Hoog, J, Mudd, JL, Dean, DA, Patidar, R, Chen, L, Wyczalkowski, MA, Jayasinghe, R, Rodrigues, FM, Terekhanova, NV, Li, Y, Lim, KH, Wang-Gillam, A, Van Tine, BA, Ma, C, Aft, R, Fuh, KC, Schwarz, JK, Roth, JA, Tapia, C, Yang, F, Akcakanat, A, Chen, H, Dai, B, Gibbons, DL, Ha, MJ, Jensen, VB, Kim, M, Kopetz, S, Menter, DG, Meraz, I, Sorokin, A, Wang, J, Westin, SN, Xi, Y, Yap, TA, Yennu Nanda, VG, Zhang, X, Zheng, X, Davies, MA, Fang, B, Meric-Bernstam, F Author Correction. Nature communications 13(1), 2022. PMID: 34996889.
- Ganan Gomez, I, Yang, H, Ma, F, Montalban Bravo, G, Thongon, N, Marchica, V, Richard-Carpentier, G, Chien, KS, Manyam, GC, Wang, F, Alfonso Pierola, A, Chen, S, Class, CA, Kanagal Shamanna, R, Ingram, JP, Ogoti, Y, Rose, A, Loghavi, S, Lockyer, P, Cambo, B, Muftuoglu, M, Schneider, S, Ademà Llobet, V, McLellan, MD, Garza, J, Marchesini, M, Giuliani, N, Pellegrini, M, Wang, J, Walker, J, Li, Z, Takahashi, K, Leverson, JD, Bueso-Ramos, CE, Andreeff, M, Dwyer, KC, Garcia-Manero, G, Colla, S Author Correction. Nature medicine 28(5):1097, 2022. PMID: 35484266.
- Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Maria Della Corte C, Fan Y, Kundu K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models. bioRxiv, 2020. PMID: 32577652.
- Fang P, Rao X, Wang J, Maru D, Lin SH Differential Expression of Immuno-oncologic Genes in Esophageal Cancer Patients With Complete Pathologic Response to Chemoradiation. Int J Radiat Oncol Biol Phys 96(2S):E166, 2016.
- Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R, Atlas Network CG Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A 111(43):15544-9, 2014. PMID: 25313082.
- Lin X, Liu B, Yang X, Yue X, Diao L, Wang J, Chang J Genetic deletion of Rnd3 results in aqueductal stenosis leading to hydrocephalus through up-regulation of Notch signaling. Proc Natl Acad Sci U S A 110(20):8236-41, 2013. PMID: 23630292.
Abstracts
- Morris BB, Nabet B, Shames D, Heeke S, Gay CM, Wang J, Zhang J, Heymach JV, Byers LA. Comprehensive DNA Repair Landscape Analysis Reveals Novel Small Cell Lung Cancer Biology. AACR 2023, 2023. e-Pub 2023.
- Shah PA, Mazumdar T, Powell RT, Shen L, Wang J, Stephen CC, Frederick MJ, Johnson FM. Concurrent inactivation of PI3K and PLK1 is synergistic and overcomes acquired resistance to PI3K inhibitors in NOTCH1MUT HNSCC. AACR 2023, 2023. e-Pub 2023.
- Wang Y, Zhang Z, Tain X, Wang J, Gorlick R. Targeting Cell Adhesion Molecule 1 (CADM1) with an antibody-drug conjugate for the treatment of osteosarcoma. AACR 2023, 2023. e-Pub 2023.
- Zhang B, Yang Y, Stewart C, Ramkumar K, Wang R, Cardnell R, Diao L, Wang Q, Wang J, Byers L, Gay C, Heymach J. Subtype-specific targeting of cell surfaceome with CAR T therapies in small cell lung cancer. AACR 2023, 2023. e-Pub 2023.
- Alvarez-Cienfuegos A, Cheung LH, Mohamedali KA, Manyam GC, Wang J, Rosenblum MG. Identification of genomic pathways associated with resistance of NSCLC to immunotherapies containing granzyme B. AACR 2023, 2023. e-Pub 2023.
- Bhardwaj A, Ju Z, Albarracin CT, Trinidad C, Mistretta B, Gunaratne P, Wang J, Zein RE, Bedrosian I. Subtype-specific molecular signatures of field cancerization in patients with sporadic breast cancer. AACR 2023, 2023. e-Pub 2023.
- Ramkumar K, Stewart C, Tanimoto A, Wang Q, Xi Y, Wang R, Shen L, Cardnell RJ, Wang J, Gay CM, Byers LA. Combined inhibition of AXL and ATR enhances replication stress, cell death and immune responses in small cell lung cancer. AACR 2023, 2023. e-Pub 2023.
- Meraz IM, Majidi M, Song R, Feng M, Gao L, Wang Q, Wang J, Shpall E, Roth JA. NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (NSCLC) in a humanized mouse model. AACR 2023, 2023. e-Pub 2023.
- Negrao MV, Araujo HA, Wang J, Lamberti G. Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC,. AACR 2023, 2023. e-Pub 2023.
- Gay CM, Stewart C, Frumovitz M, Fujimoto J, Xi Y, Runsheng Wang QW, Novegil V, Altan M, Cascone T, Dasari A, Elamin YY, Fossella FV, Glisson BS, Lu CS, Negrao MV, Skoulidis F, Cardnell RJ, Wistuba II, Wang J, Heymach JV, Byers LA. A Phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas. AACR 2023, 2023. e-Pub 2023.
- Stewart C, Diao L, Xi Y, Wang R, Ramkumar K, Rodriguez L, Morris BB, Shen L, Zhang B, Yang Y, Tanimoto A, Novegil VY, Soto LS, Rocha PD, Vokes N, Gibbons D, Frumovitz M, Fujimoto J, Wang J, Byers LA, Gay CM. YAP1 in relapsed pulmonary high-grade neuroendocrine carcinomas (NEC) is associated with CDKN2A loss, intact RB1, EMT and therapeutic vulnerability to MEK1 and CDK4/6 inhibition. AACR 2023, 2023. e-Pub 2023.
- Zhang B, Yang Y, Stewart C, Ramkumar K, Wang R, Cardnell R, Diao L, Wang Q, Wang J, Byers L, Gay C, Heymach J. Subtype-specific targeting of cell surfaceome with CAR T therapies in small cell lung cancer. AACR 2023, 2023. e-Pub 2023.
- Morris BB, Nabet B, Shames D, Heeke S, Gay CM, Wang J, Zhang J, Heymach JV, Byers LA. Comprehensive DNA Repair Landscape Analysis Reveals Novel Small Cell Lung Cancer Biology. AACR 2023, 2023. e-Pub 2023.
- Meraz IM, Majidi M, Song R, Feng M, Gao L, Wang Q, Wang J, Shpall E, Roth JA. NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (NSCLC) in a humanized mouse model. AACR 2023, 2023. e-Pub 2023.
- Ramkumar K, Stewart C, Tanimoto A, Wang Q, Xi Y, Wang R, Shen L, Cardnell RJ, Wang J, Gay CM, Byers LA. Combined inhibition of AXL and ATR enhances replication stress, cell death and immune responses in small cell lung cancer. AACR 2023, 2023. e-Pub 2023.
- Shah PA, Mazumdar T, Powell RT, Shen L, Wang J, Stephen CC, Frederick MJ, Johnson FM. Concurrent inactivation of PI3K and PLK1 is synergistic and overcomes acquired resistance to PI3K inhibitors in NOTCH1MUT HNSCC. AACR 2023, 2023. e-Pub 2023.
- Wang Y, Zhang Z, Tain X, Wang J, Gorlick R. Targeting Cell Adhesion Molecule 1 (CADM1) with an antibody-drug conjugate for the treatment of osteosarcoma. AACR 2023, 2023. e-Pub 2023.
- Stewart C, Diao L, Xi Y, Wang R, Ramkumar K, Rodriguez L, Morris BB, Shen L, Zhang B, Yang Y, Tanimoto A, Novegil VY, Soto LS, Rocha PD, Vokes N, Gibbons D, Frumovitz M, Fujimoto J, Wang J, Byers LA, Gay CM. YAP1 in relapsed pulmonary high-grade neuroendocrine carcinomas (NEC) is associated with CDKN2A loss, intact RB1, EMT and therapeutic vulnerability to MEK1 and CDK4/6 inhibition. AACR 2023, 2023. e-Pub 2023.
- Alvarez-Cienfuegos A, Cheung LH, Mohamedali KA, Manyam GC, Wang J, Rosenblum MG. Identification of genomic pathways associated with resistance of NSCLC to immunotherapies containing granzyme B. AACR 2023, 2023. e-Pub 2023.
- Bhardwaj A, Ju Z, Albarracin CT, Trinidad C, Mistretta B, Gunaratne P, Wang J, Zein RE, Bedrosian I. Subtype-specific molecular signatures of field cancerization in patients with sporadic breast cancer. AACR 2023, 2023. e-Pub 2023.
- Gay CM, Stewart C, Frumovitz M, Fujimoto J, Xi Y, Runsheng Wang QW, Novegil V, Altan M, Cascone T, Dasari A, Elamin YY, Fossella FV, Glisson BS, Lu CS, Negrao MV, Skoulidis F, Cardnell RJ, Wistuba II, Wang J, Heymach JV, Byers LA. A Phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas. AACR 2023, 2023. e-Pub 2023.
- Negrao MV, Araujo HA, Wang J, Lamberti G. Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC,. AACR 2023, 2023. e-Pub 2023.
- Wang J, Do K, Wen S, Tsavachidis S, McDonnell T, Coombes K. Correlating microarray gene expression measurements with Gleason scores and identifying biomarkers to distinguish prostate cancer stages: A meta-analysis approach. Eastern North American Regional/International Biometric Society (ENAR) 2005, Austin, TX, 2005. e-Pub 2005.
- Wang J, Do K, Wen S, Tsavachidis S, McDonnell T, Coombes K. Correlating microarray gene expression measurements with Gleason scores and identifying biomarkers to distinguish prostate cancer stages: A meta-analysis approach. Eastern North American Regional/International Biometric Society (ENAR) 2005, Austin, TX, 2005. e-Pub 2005.
- Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold D, Ross J, Hess K, Tirrell S, Linette G, Hortobagyi G, Symmans W, Pusztai L. Cross platform comparison of multigene predictors of response to neoadjuvant chemotherapy. The American Society of Clinical Oncology (ASCO), 2004. e-Pub 2004.
- Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold D, Ross J, Hess K, Tirrell S, Linette G, Hortobagyi G, Symmans W, Pusztai L. Cross platform comparison of multigene predictors of response to neoadjuvant chemotherapy. The American Society of Clinical Oncology (ASCO), 2004. e-Pub 2004.
- Stivers D, Wang J, Rosner G, Coombes K. Organ-Specific Differences in Gene Expression and UniGene Annotations Describing Source Material. Critical Assessment of Techniques for Microarray Data Analysis (CAMDA’02), Duke University, Durham, N.C, 2002. e-Pub 2002.
- Stivers D, Wang J, Rosner G, Coombes K. Organ-Specific Differences in Gene Expression and UniGene Annotations Describing Source Material. Critical Assessment of Techniques for Microarray Data Analysis (CAMDA’02), Duke University, Durham, N.C, 2002. e-Pub 2002.
- Coombes K, Baggerly K, Stivers D, Wang J, Gold D, Sung H, Lee S. Biology-Driven Clustering of Microarray Data: Applications to the NCI60 Data Set. Critical Assessment of Techniques for Microarray Data Analysis (CAMDA’01), Duke University, Durham, N.C, 2001. e-Pub 2001.
- Coombes K, Baggerly K, Stivers D, Wang J, Gold D, Sung H, Lee S. Biology-Driven Clustering of Microarray Data: Applications to the NCI60 Data Set. Critical Assessment of Techniques for Microarray Data Analysis (CAMDA’01), Duke University, Durham, N.C, 2001. e-Pub 2001.
Book Chapters
- Baggerly K, Morris J, Wang J, Gold D, Xiao L, Coombes K. Comprehensive Approach to the Analysis of MALDI-TOF Proteomics Spectra from Serum Samples . In: Proteomics 3, 1667-72, 2003.
- Coombes K, Wang J, Abruzzo L. Monitoring the quality of microarray experiments. In: Methods of Microarray Data Analysis, 2003.
- Stivers D, Wang J, Rosner G, Coombes K. Organ-Specific Differences in Gene Expression and UniGene Annotations Describing Source Material. In: Methods of Microarray Data Analysis, 2003.
- Coombes K, Baggerly K, Stivers D, Wang J, Gold D, Sung H, Lee S. Biological-Driven Cluster of Microarray Data. In: Methods of Microarray Data Analysis. Kluwer Academic Publishers, 2002.
- Wang J, Coombes K, Baggerly K, Hu L, Hamilton S, Zhang W. Statistical Considerations in the Assessment of cDNA Microarray Data Obtained Using Amplification. In: Computational and Statistical Approaches To Genomics. Kluwer Academic Publishers, 2002.
Letters to the Editor
- Akiyama, H, Nishida, Y, Chang, KH, Bedoy, AD, Muftuoglu, M, Ma, W, Basyal, M, Hirschi, Z, Honma, D, Tsutsumi, S, Wang, J, Zhang, W, Huang, X, Rampal, R, Oluwole, OO, Bixby, D, Daver, N, Andreeff, M. Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia. Blood cancer journal 15, 2025.
- Parchem, JG, Fan, H, Mann, LK, Campbell, KM, Yang, S, Ma, W, Won, JH, Wang, J, Papanna, R, Kalluri, R. Amniotic fluid extracellular vesicle and cell-free RNA profiling reveals fetal adaptations in twin-twin transfusion syndrome. American Journal of Obstetrics and Gynecology MFM 7, 2025.
Patents
- Wang J. Lung Permeability Analysis. Patent Number: 5916152.
Patient Reviews
CV information above last modified April 01, 2026